黄芪多糖干预树突状细胞基因表达与动脉粥样硬化斑块关系的研究
|
摘要
冠心病(coronary heart disease,CHD)作为进入二十世纪以来,威胁人类生命健康的主要疾病,其有效防治一直成为整个社会关注的重点和难点。但是CHD的发病机制至今仍不明了,成为阻滞其治疗进展的主要难题。动脉粥样硬化(atherosclerosis,AS)是心脑血管疾病的发病的主要病理基础。以往关于AS形成的机制主要围绕三种学说,脂质沉淀学说、损伤修复学说和血栓形成学说。因而,高龄、血脂升高、吸烟、血压升高、血糖升高、高半胱氨酸血症以及高尿酸血症等导致血管内皮损伤和脂质沉积的内在因素,被界定为CHD发病的高危因素。远离这些危险因素,或者控制这些因素的恶化,在一定程度上取得了预防AS发生发展的成果。然而,随着CHD发病的逐渐年轻,进展逐渐加快,使得人们对危险因素的预防治疗提出了疑问。近年来,随着急性冠脉综合症(acutecoronary syndrome,ACS)这个CHD的急性进展阶段的界定,使得人们重新认识了CHD发展阶段的病理和病理生理特点。研究发现ACS的病理基础是易损斑块,并且发现易损斑块伴随着大量炎症细胞和免疫细胞的介入,是斑块不稳定和容易破裂的主要原因;ACS患者存在全身炎症因子和炎症反应活化的情况。进而,发现AS的所有阶段都有免疫细胞的介入,提出CHD是一种慢性炎症和自身免疫性疾病这一新观点,认为内在或外在危险因素导致的炎症和免疫反应是AS发病的基础。
树突状细胞(Dendritic cells,DCs)是免疫过程中起负责抗原呈递的细胞,是机体内功能最强的专职抗原呈递细胞。极少量的DCs即可强烈激活T淋巴细胞启动特异性细胞免疫反应,其激活T淋巴细胞的能力是巨噬细胞或B细胞的100～1000倍,在免疫应答的诱导和调节中起重要作用。最近研究证实在动脉壁中有引起免疫反应发生的微环境,正常动脉内膜存在一种血管相关淋巴组织(Vascular-associated lymphoid tissue,VALT),类似于呼吸道和胃肠道中的粘膜相关淋巴组织,散在分布着一些由免疫活性细胞和抗原呈递细胞组成的细胞群,对血管组织中可能有害的内源性或外源性抗原进行监视和筛查。VALT中发现有血管树突状细胞(Vascular dendritic cells,VDCs)的存在,正常的动脉壁中VDCs较少,属未成熟形式,主要分布在血管的内膜和外膜。VDCs在AS病变中聚集明显增加,在炎症浸润区域往往与T淋巴细胞和巨噬细胞聚集在一起。DCs与T淋巴细胞共同出现在AS的病变薄弱部位,使得人们推测DCs在AS的发生发展中可能同样起着启动炎症和免疫反应的作用。最近的研究显示氧化修饰的低密度脂蛋白和尼古丁可通过激活DCs介导的获得性免疫反应,促进AS病变的进展。说明DCs可能参与了AS的病理发生,在触发和放大AS炎症免疫反应中起重要的调节作用。
黄芪多糖(Astragalus polysaccharids,APS)是黄芪中重要的天然有效成分之一,具有双向调节血糖、促进免疫、提高巨噬细胞活性、促进淋巴细胞转化,激活T细胞B细胞并能促进抗体的形成,从而抗击各种病毒性和细菌性疾病,此外,研究发现APS在多种疾病中发挥重要作用,如APS具有抗肿瘤作用,但体外实验表明APS不能有效抑制肿瘤细胞生长,推测其抗肿瘤作用可能与APS的免疫诱导作用有关。APS可显著降低非肥胖小鼠1型糖尿病的发病率,保护胰腺小岛的超微结构,恢复Th1细胞群和Th2细胞群间平衡。APS能够降低SD大鼠肾皮质NF-κB mRNA水平的表达,提高IκB mRNA的表达,可有效的防治糖尿病肾病的进展。APS能够有效抑制金属诱导的氧化应激,抑制肾脏的缺血再灌注损伤,调控免疫反应,抑制肾小球系膜细胞增殖和基质的过度合成以及下调肾小球系膜细胞β1整合素的表达。在心血管疾病相关研究中,APS能有效降低健康人总胆固醇、载脂蛋白H、低密度脂蛋白的水平,对50岁以上中老年健康人群的三酰甘油水平也同样有效。在对糖尿病心肌病仓鼠模型的研究中,APS通过抑制仓鼠局部心肌糜蛋白酶-AngⅡ系统发挥抗仓鼠糖尿病心肌病的作用。此外,有研究表明APS是通过抑制血小板钙调蛋白而抑制磷酸二酯酶的活性,从而增加血小板内cAMP含量,抑制血小板聚集和血栓形成。此外,APS是黄芪注射液的主要成分之一,在对冠心病心绞痛的治疗中,黄芪注射液能明显减少心绞痛的发作次数,延长发作间歇时间,临床疗效改善显著。黄芪注射液能够干预CHD发生发展可能与APS的免疫调节功能密不可分。
由于DCs作为联系天然防御功能和获得性免疫的关键,与CHD发生发展密切相关,那么在CHD治疗中,APS是否通过作用于DCs发挥免疫调节功能?APS处理后具有抗原呈递功能的DCs功能状态如何,是否会影响其功能蛋白和免疫调节分子的分泌,是否会影响这些蛋白的基因表达。这些问题中,研究APS处理后DCs的基因变化是问题关键。
本课题分为三个部分,将分离的临床人外周血单核细胞(peripheral bloodmononuclear cell,PBMC)和血清为研究对象,以研究APS处理后外周血PBMC源性DCs基因表达和功能变化为切入点,通过免疫荧光、流式细胞术、基因芯片、RT-PCR和ELISA等方法,重点观察APS处理外周血PBMC源性DCs的成熟状态、免疫功能和其他基因表达的差异与AS发生发展的关系,深入探讨APS处理后抗原呈递细胞功能变化在AS治疗过程的地位和作用。旨在为AS发生发展的免疫介导学说提供实验依据和免疫治疗途径,为心脑血管疾病的防治提供新的理论平台和技术手段,具有长远的经济价值和重要的社会意义。结果分述如下:
1.APS处理后人外周血来源的DCs处于成熟状态,并具有诱导T细胞增殖的能力
1.1人外周血来源的DCs培养与鉴定
培养第2天对照组细胞粘附于聚苯乙烯培养瓶底部,实验组的细胞部分在培养基中悬浮生长,细胞较小,形态无明显差别。培养第6天对照组的细胞呈圆形或椭圆形,大部分粘附于培养瓶瓶底;LPS组、100mg/L APS组的细胞生长状态最好,呈悬浮生长,可见部分细胞聚集成簇,细胞表面可见数量不等、形态不一的树突样突起。200mg/L APS组多数细胞胞质内可见大量空泡样结构,可见细胞崩解,有大量不定型的细胞碎片。流式细胞仪检测APS100mg/L组人外周血PBMC来源的DCs表型为CD1α~+,CD80~+,CD83~(low),CD86~+,HLA-DR~+。
1.2 DCs培养上清液细胞因子IL-12检测结果
因200mg/L组细胞大量凋亡崩解,故选择对照组、LPS组、50mg/L APS组、100mg/L APS组细胞上清液中IL-12进行检测。培养6天后,4组细胞上清液中IL-12含量存在显著性差异(P=0.000);其中,LPS组、100mg/L APS组细胞上清液中IL-12含量分别与对照组、50mg/L APS组相比存在显著性差异(P=0.000),明显高于后两组。
1.3各组外周血PBMC来源的DCs表型变化情况
选择对照组、50mg/L APS组、100mg/L APS组、LPS组进行流式细胞学检测。100mg/L APS组、LPS组DCs表面CD1α、CD86等表型表达上调,与对照组、50mg/L APS组相比,存在显著性差异(P＜0.05);LPS组HLA-DR表达与50mg/L APS组相比,存在显著性差异(P＜0.05),50mg/L APS组HLA-DR表达较低。而各组DCs表面CD83表型表达各组之间差异无显著性意义。
1.4各组DCs的同种混合淋巴细胞反应
~3H-TDR掺入率在4组间存在显著性差异(P＜0.01)。DCs在与T淋巴细胞混合比例在1∶50、1∶20时,100mg/L APS组、LPS组的~3H-TDR掺入率与其他两组相比,存在显著性差异(P＜0.01),较其余两组明显升高;而对照组、50mg/LAPS组之间的~3H-TDR掺入率相比,无显著性学差异(P＞0.05)。
2.基因芯片检测外周血PBMC来源的DCs基因表达不同
芯片检测的结果显示,APS处理后人外周血DCs功能蛋白表达基因中有7个基因呈明显上升,分别是CD36、IGSF6、IL27、INHA、LIPA、MAP4K3和SOD2,分别属于抗原识别受体、细胞因子、细胞酶类和细胞内信号传导系统。有26个基因呈明显下降表达,分别是ADAM19、ADAR、BASP1、BTG1、CCR7、CD40LG、CST7、CXCL9、CXCR4、DCTN2、EBI3、ISG15、ICAM1、IFI16、IL15、ISG20、CD207、LTA、MARCKS、MARCKSL1、NFKB1、NFKB2、PNRC1、RAC1、RELB和TNFRSF11B等,分别属于细胞酶类、抗原识别受体、细胞趋化因子受体、细胞因子和细胞内信号传导系统。APS处理后人外周血PBMC来源的DCs分别在细胞粘附及趋化DCs迁徙的受体及相关蛋白如ADAM19、CCR7、CD40LG、CST7、CXCL9和CXCR4等的表达减低;而与诱导细胞增殖及活化相关的信号传导通路及功能蛋白的基因表达如ADAR、BASP1、BTG1、DCTN2、ISG15、ISG20、MARCKS、MARCKSL1、NFKB1、NFKB2、PNRC1、RAC1、RELB和TNFRSF11B也同样下降;而与抗原呈递及诱导免疫反应相关蛋白的基因表达如EBI3、IFI16、IL15、CD207和LTA等表达下降。而作为升高的表达基因,有抗原结合蛋白基因如CD36;有消化及降解抗原的相关细胞及溶酶体酶类蛋白如LIPA和SOD2;同样有抑制炎症及免疫反应的蛋白基因表达增多,如IL27和INHA等。
3.荧光定量PCR检测基因芯片结果,显示DCs基因芯片检测有较好的可信度
应用荧光定量PCR检测芯片检测表达上调的基因CD36和IL-27,以及表达下调的基因FIF16表达情况显示,APS处理后DCs组CD36和IL-27基因表达较对照组增加幅度与基因芯片检测相似;而FIF16基因表达较对照组降低加幅度与基因芯片检测相似。
通过上述三个部分的实验,我们能够得出以下结论:
①APS处理人外周血PBMC源的DCs细胞形态及表型表达处于成熟状态;
②APS处理人外周血PBMC源的DCs,分泌IL-12水平较对照组明显升高,且具有诱导同种T淋巴细胞增殖的能力;
③APS处理后人外周血DCs功能蛋白表达基因中有7个基因呈明显上升,分别是CD36、IGSF6、IL27、INHA、LIPA、MAP4K3和SOD2,分别属于抗原识别受体、细胞因子、细胞酶类和细胞内信号传导系统。有26个基因呈明显下降表达,分别是ADAM19、ADAR、BASP1、BTG1、CCR7、CD40LG、CST7、CXCL9、CXCR4、DCTN2、EBI3、ISG15、ICAM1、IFI16、IL15、ISG20、CD207、LTA、MARCKS、MARCKSL1、NFKB1、NFKB2、PNRC1、RAC1、RELB和TNFRSF11B等,分别属于细胞酶类、抗原识别受体、细胞趋化因子受体、细胞因子和细胞内信号传导系统。
④荧光定量PCR检测芯片检测表达上调的基因CD36和IL-27,以及表达下调的基因IFI16表达情况,验证了芯片检测的结果。
Coronary heart disease(CHD)has been the main threaten to human health since the arrival of 21th century.The effective prevention and treatment of CHD has being the emphasis and challenge of the whole society of human beings.However,the pathogenesis of CHD has not been clearly identified so it is a great hindrance to the clinical treatment of CHD.Atherosclerosis(AS)is the pathologic basis of cardiac cerebro vascular diseases.In the past,there were mainly 3 theories,including lipidose deposition,injury repair and thrombogenesis,to explain the forming of AS.On basis of these theories,factors such as aging,hyperlipemia,hypertension,hyperglycaemia, hypercysteinemia and high blood uric acid are termed as high risks of CHD because they may induce blood vessel endothelium injury and lipidose deposition.Some progresses have been made in prevention of the genesis and advancement of AS by getting rid of or controlling of these high risks.However,people are beginning to question the effects of the preventions and treatments on these high risks for that the morbility age of CHD are younger than ever before,and the progress of AS speeds up. With the terming of ACS on acute progress stages of CHD,People re-recognized the pathologic and pathophysiologic characteristics of CHD in their developmental stages. Studies on AS found that unstable plaques are the pathological basis of ACS.The interventions of the inflammatory cells and immunocells to unstable plaques are key factors that leading to the instability and easily rupture of AS plaques.It is considered that systemic activation of the inflammatory factors and inflammatory reactions exist in ACS cases.What's more,people found that immunocells involve in all the AS developmental stages.They had proposed a new point of view that CHD is a process of chronic inflammation and a disease of autoimmunity.It is considered that inflammatory reactions and immune reactions induced by endogenous and exogenous risks are the pathological basis of AS.
Dendritic cells(DCs)are the most powerful specific antigen presenting cells that play a role of presenting antigens in the immunologic process.Minor DCs may intensively activate T cells,which may initiate the specific cellular immunity reaction. Their capacities of T cells activation are as 100-1000 folds as that of macrophages. They play an important role in the induction and regulation of immunologic response. It is confirmed by recent studies that arterial wall may offer a good microenviroment to the immunological reactions.A Vascular-associated lymphoid tissue(VALT)that similar to mucous membrane-associated lymphoid tissue in respiratory tract and gastrointestinal tract,exist in the normal endarterium.Some cell masses which are comprised of immunological competent cells and antigen presenting cells distribute diffusedly in these tissues.They may monitor and screen the potential endogeneous or exogenous harmful antigens in the vascular tissues.Vascular dendritic cells(VDCs) can be found in VALT.Normally speaking,only a very small number of VDCs which in an immature form,can be found in the vessel tunica intima and tunica adventitia. Aggregation of VDCs in the affected regions increase and,they always aggregate with T cells and macrophages in the inflammatory infilitrated regions.People presume that DCs may play a role in initiating inflammatory and immunological reactions in the genesis and development of AS for that DCs co-emerge with T cells in the weak affected regions.Recent studies showed that oxidated LDL and nicotine may promote the advancement of AS by activating DCs-mediated acquired immunological reactions.This suggest that DCs may play a role in the pathogenesis of AS and that they may play an important role in the regulation of the triggering and amplification of inflammatory and immunological reactions in AS.
Astragalus polysaccharids,one of the most important natural active ingredients in Astragalus,have the function of bi-directional regulation of blood sugar,promoting immunity,enhancing macrophage activity and promoting the transformation of lymphocyte,activating T cells,B cells and promoting the formation of antibodies in order to fight against various viral and bacterial diseases.In addition,the study found that APS play an important role in various diseases,for instance,APS have anti-tumor effect,but APS can not inhibit effectively the growth of tumor cells in vitro, suggesting that its anti-tumor effects of APS may be associated with immune effects. APS can reduce the incidence of type 1 diabetes of the non-obese mice significantly, and protect the the ultrastructure of pancreatic islets,restore the balance between Th1 cells and Th2 cells.APS can reduce NF-kB mRNA expression levels in the renal cortex of SD rats,enhance the expression of IkB mRNA,and can control the progress of diabetic nephropathy effectively.APS can inhibit metal-induced oxidative stress and renal ischemia-reperfusion injury,stimulate the immune regulation,inhibit glomerular mesangial cell proliferation and matrix synthesis,as well as reduced the expression ofβ1 integrin in mesangial cell.In relation with the research of cardiovascular disease,APS can reduce total cholesterol,apolipoprotein H, low-density lipoprotein level of healthy people effectively,as well as triglycerides levels in more than 50-year-old middle-aged healthy population.On the study of the hamster model of diabetic cardiomyopathy,APS exert the effect of anti-diabetic cardiomyopathy by inhibiting the chymotrypsin-AngⅡsystem.Besides,more studies have shown that astragalus polysaccharide increase the content of cAMP in platelets and inhibit platelet aggregation and thrombosis through the inhibition of platelet calmodulin and phosphodiesterase activity.Moreover,Astragalus Polysaccharides are one of the major components in Astragalus injection,and in the treatment of angina pectoris,Astragalus injection can reduce the number of angina attacks,extend the attack time interval,improve the clinical efficacy significantly. Above all,Astragalus injection intervening in the development of CHD may be related to the immune regulation function of APS.
Considering that DCs are key in natural defense and acquired immune and closely related to the occurrence and development of CHD,so in the treatment of CHD,whether APS play a role in regulating immune function though exerting on DCs?After treatment with APS,how the DCs functional status in antigen-presenting, and whether affect secretion of the functional proteins and immunomodulatory molecules,and the gene expression of these proteins in DCs or not.Study on genetic changes of DCs is the key in resolving these problems.
Our studies can mainly be divided into 3 portions.Peripheral blood mononuclear cell(PBMC)and serum abstracted from clinical cases are the objectives of our study.The gene expressions and functional changes of PBMC derived DCs after treatment with APS is the starting point in our study.Through immunofluorescence,flow cytometry,DNA microarray,RT-PCR and ELISA,we have focused on the relationship between the occurrence and development of AS and mature status,immune function and other gene expression differences of PBMC peripheral blood-derived DCs after APS treatment,and discussed deeply the status and the role of antigen-presenting cell function after treatment with APS in the treatment of AS.Aiming to provide an experimental evidence and target of immune therapy for the immune-mediated hypothesis in the development of AS,and review new theoretical platform and technical mean for the prevention and treatment of cardio-cerebrovascular disease,this study have the long-term economic value and important social significance.The results are as follows:
1.DCs derived from peripheral blood in a mature state after APS treatment,have the ability to induce T cell proliferation.
1.1 Culture and identification of DCs
In cultured 2 day,cells adhesion to the bottom of polystyrene bottle in the control group,part cells are suspended growth in medium in the experimental group, smaller,and no significant difference shape.In cultured 6 day,cells adhesion to the culture bottle bottom with round or oval in shape in control group;cells,showing suspended growth in medium,part of them aggregation in clusters,dendritic-like protrusionsin on cell surface in different quatity and shape,have the best growth status in LPS group,100mg/L group.Large number of vacuoles-like structure in the majority of the cytoplasm cell,collapsed cells,and a large number of atypical cell debris can be seen in 200mg/L APS group.In APS 100mg/L group,the phenotype of human peripheral blood PBMC derived DCs are CD1α~+,CD80~+,CD83~(low),CD86~+, HLA-DR~+by flow cytometry analysis.
1.2 Detection cytokine IL-12 in cultured supernatant.
Because of a large number of apoptotic cells in 200mg/L,the control group,LPS group,50mg/L APS group,100mg/L APS have been chosed to detect the cytokine IL-12 in cell supernatant.In culture 6 days,the content of IL-12 have significantly statistical difference in 4 groups of cells cultured supernatant(P=0.000);compared the content of IL-12 in cells cultured supernatant of LPS group,l00mg/L APS with the control group,50mg/L APS group,there have significantly statistical difference (P=0.000),and the content of IL-12 in cells cultured supernatant in the fomer two groups significantly higher than in the latter two groups.
1.3 The phenotype of peripheral blood PBMC derived DCs varied in each group.
Because of a large number of apoptotic cells in 200mg/L,the control group,LPS group,50mg/L APS group,l00mg/L APS have been chosed to detect the phenotype of peripheral blood PBMC derived DCs varied in each group.There have statistical difference in CD1α,CD86 of DCs phenotype between l00mg/L APS group,LPS group and control group,50mg/L APS group(P＜0.05),and the CD 1α,CD86 of DCs phenotype in l00mg/L APS group,LPS group Showed up-regulated expression;there have statistical difference in HLA-DR of DCs phenotype between LPS group and 50mg/L APS group(P＜0.05),and the HLA-DR of DCs phenotype in 50mg/L APS group Showed up-regulated expression.
1.4 Allogenic mixed lymphocytic reactions in PBMC derived DCs in each group. There have a significant difference ~3H-TDR incorporation rate in 4 groups(P＜0.01).At the proportion of 1:50,1:20 of DCs mixed with T lymphocytes,there have significantly statistical difference between l00mg/L APS group,LPS group and other two groups in the rate of H-TDR incorporation(P＜0.01),and the rate of H-TDR incorporation in l00mg/L APS group,LPS group significantly higher than the other two groups;but there have no statistical difference between the control group and 50mg/L in the ~3H-TDR incorporation rate(P＞0.05)
2 Detection different gene expression of the peripheral blood PBMC derived DCs by gene chip
The result of gene chip detection show that,the expression gene of functional protein after APS treatment in peripheral blood DCs have seven genes increased markedly,they are CD36,IGSF6,IL27,INHA,LIPA,MAP4K3 and SOD2,and belong to antigen recognition receptors,cytokine,cell enzymes and cell signal transduction system.And 26 genes showed decreased expression,they are ADAM19, ADAR,BASP1,BTG1,CCR7,CD40LG,CST7,CXCL9,CXCR4,DCTN2,EBB, ISG15,ICAM1,IFI16,IL15,ISG20,CD207,LTA,MARCKS,MARCKSL1, NFKB1,NFKB2,PNRC1,RAC1,RELB and TNFRSF11B,and belong to cell enzymes,antigen recognition receptors,cytokine receptor,cytokine and cellular signal transduction systems.The peripheral blood PBMC after APS treatment are reduced in the expression of cell adhesion and chemotactic migration of DCs receptors and related proteins such as AD AM19,CCR7,CD40LG,CST7,CXCL9 and CXCR4;the gene expression with related to the induction of cell proliferation and activation signal transduction pathway and functional protein are also decreased, such as ADAR,BASP1,BTG1,DCTN2,ISG15,ISG20,MARCKS,MARCKSL1, NFKB1,NFKB2,PNRC1,RAC1,RELB and TNFRSF11B;and the gene expression with related to antigen-presenting and immune response related protein are decreased, such as EBI3,IFI16,IL15,CD207,and LTA.In upregulated expression genes,there have antigen-binding protein gene such as CD36,digestion and degradation of antigen related cell and lysosome protein gene such as LIPA and SOD2,as well as inhibition inflammation and immune responses protein gene expression such as IL27 and INHA.
3 Detection the results of gene chip by fluorescence quantitative PCR showed that gene chip have better credibility in detection DCs gene.
Application fluorescence quantitative PCR in detection of microarray gene expression of CD36 and IL-27,as well as down-regulated expression gene FIF16 showed that,compared with control group,CD36 and IL-27 gene expression in DCs group after APS treatment increased width,FIF16 gene expression decreased width is similar with gene chip detection.
Through above three-part experiment,we can draw the conclusions as follows:
①The phenotype expression in peripheral blood DCs after APS treatment are in a mature state;
②The levels IL-12 secreted in peripheral blood PBMC derived DCs after APS treatment,are significantly higher than the control group,and have the ability to induce allogenic lymphocytic proliferation;
③The expression gene of functional protein after APS treatment in peripheral blood DCs have seven genes increased markedly,they are CD36,IGSF6,IL27,INHA, LIPA,MAP4K3 and SOD2,and belong to antigen recognition receptors,cytokine, cell enzymes and cell signal transduction system.And 26 genes showed significant decreased expression,they are ADAM19,ADAR,BASP1,BTG1,CCR7,CD40LG, CST7,CXCL9,CXCR4,DCTN2,EBI3,ISG15,ICAM1,IFI16,IL15,ISG20,CD207, LTA,MARCKS,MARCKSL1,NFKB1,NFKB2,PNRC1,RAC1,RELB and TNFRSF11B,and belong to cell enzymes,antigen recognition receptors,cytokine receptor,cytokine and cellular signal transduction systems.
④Detection the CD36 and IL-27 gene which upregulated expression,and IFI16 gene which downregulated expression in microarray by fluorescence quantitative PCR,verified the results of the gene microarray.
树突状细胞(Dendritic cells,DCs)是免疫过程中起负责抗原呈递的细胞,是机体内功能最强的专职抗原呈递细胞。极少量的DCs即可强烈激活T淋巴细胞启动特异性细胞免疫反应,其激活T淋巴细胞的能力是巨噬细胞或B细胞的100～1000倍,在免疫应答的诱导和调节中起重要作用。最近研究证实在动脉壁中有引起免疫反应发生的微环境,正常动脉内膜存在一种血管相关淋巴组织(Vascular-associated lymphoid tissue,VALT),类似于呼吸道和胃肠道中的粘膜相关淋巴组织,散在分布着一些由免疫活性细胞和抗原呈递细胞组成的细胞群,对血管组织中可能有害的内源性或外源性抗原进行监视和筛查。VALT中发现有血管树突状细胞(Vascular dendritic cells,VDCs)的存在,正常的动脉壁中VDCs较少,属未成熟形式,主要分布在血管的内膜和外膜。VDCs在AS病变中聚集明显增加,在炎症浸润区域往往与T淋巴细胞和巨噬细胞聚集在一起。DCs与T淋巴细胞共同出现在AS的病变薄弱部位,使得人们推测DCs在AS的发生发展中可能同样起着启动炎症和免疫反应的作用。最近的研究显示氧化修饰的低密度脂蛋白和尼古丁可通过激活DCs介导的获得性免疫反应,促进AS病变的进展。说明DCs可能参与了AS的病理发生,在触发和放大AS炎症免疫反应中起重要的调节作用。
黄芪多糖(Astragalus polysaccharids,APS)是黄芪中重要的天然有效成分之一,具有双向调节血糖、促进免疫、提高巨噬细胞活性、促进淋巴细胞转化,激活T细胞B细胞并能促进抗体的形成,从而抗击各种病毒性和细菌性疾病,此外,研究发现APS在多种疾病中发挥重要作用,如APS具有抗肿瘤作用,但体外实验表明APS不能有效抑制肿瘤细胞生长,推测其抗肿瘤作用可能与APS的免疫诱导作用有关。APS可显著降低非肥胖小鼠1型糖尿病的发病率,保护胰腺小岛的超微结构,恢复Th1细胞群和Th2细胞群间平衡。APS能够降低SD大鼠肾皮质NF-κB mRNA水平的表达,提高IκB mRNA的表达,可有效的防治糖尿病肾病的进展。APS能够有效抑制金属诱导的氧化应激,抑制肾脏的缺血再灌注损伤,调控免疫反应,抑制肾小球系膜细胞增殖和基质的过度合成以及下调肾小球系膜细胞β1整合素的表达。在心血管疾病相关研究中,APS能有效降低健康人总胆固醇、载脂蛋白H、低密度脂蛋白的水平,对50岁以上中老年健康人群的三酰甘油水平也同样有效。在对糖尿病心肌病仓鼠模型的研究中,APS通过抑制仓鼠局部心肌糜蛋白酶-AngⅡ系统发挥抗仓鼠糖尿病心肌病的作用。此外,有研究表明APS是通过抑制血小板钙调蛋白而抑制磷酸二酯酶的活性,从而增加血小板内cAMP含量,抑制血小板聚集和血栓形成。此外,APS是黄芪注射液的主要成分之一,在对冠心病心绞痛的治疗中,黄芪注射液能明显减少心绞痛的发作次数,延长发作间歇时间,临床疗效改善显著。黄芪注射液能够干预CHD发生发展可能与APS的免疫调节功能密不可分。
由于DCs作为联系天然防御功能和获得性免疫的关键,与CHD发生发展密切相关,那么在CHD治疗中,APS是否通过作用于DCs发挥免疫调节功能?APS处理后具有抗原呈递功能的DCs功能状态如何,是否会影响其功能蛋白和免疫调节分子的分泌,是否会影响这些蛋白的基因表达。这些问题中,研究APS处理后DCs的基因变化是问题关键。
本课题分为三个部分,将分离的临床人外周血单核细胞(peripheral bloodmononuclear cell,PBMC)和血清为研究对象,以研究APS处理后外周血PBMC源性DCs基因表达和功能变化为切入点,通过免疫荧光、流式细胞术、基因芯片、RT-PCR和ELISA等方法,重点观察APS处理外周血PBMC源性DCs的成熟状态、免疫功能和其他基因表达的差异与AS发生发展的关系,深入探讨APS处理后抗原呈递细胞功能变化在AS治疗过程的地位和作用。旨在为AS发生发展的免疫介导学说提供实验依据和免疫治疗途径,为心脑血管疾病的防治提供新的理论平台和技术手段,具有长远的经济价值和重要的社会意义。结果分述如下:
1.APS处理后人外周血来源的DCs处于成熟状态,并具有诱导T细胞增殖的能力
1.1人外周血来源的DCs培养与鉴定
培养第2天对照组细胞粘附于聚苯乙烯培养瓶底部,实验组的细胞部分在培养基中悬浮生长,细胞较小,形态无明显差别。培养第6天对照组的细胞呈圆形或椭圆形,大部分粘附于培养瓶瓶底;LPS组、100mg/L APS组的细胞生长状态最好,呈悬浮生长,可见部分细胞聚集成簇,细胞表面可见数量不等、形态不一的树突样突起。200mg/L APS组多数细胞胞质内可见大量空泡样结构,可见细胞崩解,有大量不定型的细胞碎片。流式细胞仪检测APS100mg/L组人外周血PBMC来源的DCs表型为CD1α~+,CD80~+,CD83~(low),CD86~+,HLA-DR~+。
1.2 DCs培养上清液细胞因子IL-12检测结果
因200mg/L组细胞大量凋亡崩解,故选择对照组、LPS组、50mg/L APS组、100mg/L APS组细胞上清液中IL-12进行检测。培养6天后,4组细胞上清液中IL-12含量存在显著性差异(P=0.000);其中,LPS组、100mg/L APS组细胞上清液中IL-12含量分别与对照组、50mg/L APS组相比存在显著性差异(P=0.000),明显高于后两组。
1.3各组外周血PBMC来源的DCs表型变化情况
选择对照组、50mg/L APS组、100mg/L APS组、LPS组进行流式细胞学检测。100mg/L APS组、LPS组DCs表面CD1α、CD86等表型表达上调,与对照组、50mg/L APS组相比,存在显著性差异(P＜0.05);LPS组HLA-DR表达与50mg/L APS组相比,存在显著性差异(P＜0.05),50mg/L APS组HLA-DR表达较低。而各组DCs表面CD83表型表达各组之间差异无显著性意义。
1.4各组DCs的同种混合淋巴细胞反应
~3H-TDR掺入率在4组间存在显著性差异(P＜0.01)。DCs在与T淋巴细胞混合比例在1∶50、1∶20时,100mg/L APS组、LPS组的~3H-TDR掺入率与其他两组相比,存在显著性差异(P＜0.01),较其余两组明显升高;而对照组、50mg/LAPS组之间的~3H-TDR掺入率相比,无显著性学差异(P＞0.05)。
2.基因芯片检测外周血PBMC来源的DCs基因表达不同
芯片检测的结果显示,APS处理后人外周血DCs功能蛋白表达基因中有7个基因呈明显上升,分别是CD36、IGSF6、IL27、INHA、LIPA、MAP4K3和SOD2,分别属于抗原识别受体、细胞因子、细胞酶类和细胞内信号传导系统。有26个基因呈明显下降表达,分别是ADAM19、ADAR、BASP1、BTG1、CCR7、CD40LG、CST7、CXCL9、CXCR4、DCTN2、EBI3、ISG15、ICAM1、IFI16、IL15、ISG20、CD207、LTA、MARCKS、MARCKSL1、NFKB1、NFKB2、PNRC1、RAC1、RELB和TNFRSF11B等,分别属于细胞酶类、抗原识别受体、细胞趋化因子受体、细胞因子和细胞内信号传导系统。APS处理后人外周血PBMC来源的DCs分别在细胞粘附及趋化DCs迁徙的受体及相关蛋白如ADAM19、CCR7、CD40LG、CST7、CXCL9和CXCR4等的表达减低;而与诱导细胞增殖及活化相关的信号传导通路及功能蛋白的基因表达如ADAR、BASP1、BTG1、DCTN2、ISG15、ISG20、MARCKS、MARCKSL1、NFKB1、NFKB2、PNRC1、RAC1、RELB和TNFRSF11B也同样下降;而与抗原呈递及诱导免疫反应相关蛋白的基因表达如EBI3、IFI16、IL15、CD207和LTA等表达下降。而作为升高的表达基因,有抗原结合蛋白基因如CD36;有消化及降解抗原的相关细胞及溶酶体酶类蛋白如LIPA和SOD2;同样有抑制炎症及免疫反应的蛋白基因表达增多,如IL27和INHA等。
3.荧光定量PCR检测基因芯片结果,显示DCs基因芯片检测有较好的可信度
应用荧光定量PCR检测芯片检测表达上调的基因CD36和IL-27,以及表达下调的基因FIF16表达情况显示,APS处理后DCs组CD36和IL-27基因表达较对照组增加幅度与基因芯片检测相似;而FIF16基因表达较对照组降低加幅度与基因芯片检测相似。
通过上述三个部分的实验,我们能够得出以下结论:
①APS处理人外周血PBMC源的DCs细胞形态及表型表达处于成熟状态;
②APS处理人外周血PBMC源的DCs,分泌IL-12水平较对照组明显升高,且具有诱导同种T淋巴细胞增殖的能力;
③APS处理后人外周血DCs功能蛋白表达基因中有7个基因呈明显上升,分别是CD36、IGSF6、IL27、INHA、LIPA、MAP4K3和SOD2,分别属于抗原识别受体、细胞因子、细胞酶类和细胞内信号传导系统。有26个基因呈明显下降表达,分别是ADAM19、ADAR、BASP1、BTG1、CCR7、CD40LG、CST7、CXCL9、CXCR4、DCTN2、EBI3、ISG15、ICAM1、IFI16、IL15、ISG20、CD207、LTA、MARCKS、MARCKSL1、NFKB1、NFKB2、PNRC1、RAC1、RELB和TNFRSF11B等,分别属于细胞酶类、抗原识别受体、细胞趋化因子受体、细胞因子和细胞内信号传导系统。
④荧光定量PCR检测芯片检测表达上调的基因CD36和IL-27,以及表达下调的基因IFI16表达情况,验证了芯片检测的结果。
Coronary heart disease(CHD)has been the main threaten to human health since the arrival of 21th century.The effective prevention and treatment of CHD has being the emphasis and challenge of the whole society of human beings.However,the pathogenesis of CHD has not been clearly identified so it is a great hindrance to the clinical treatment of CHD.Atherosclerosis(AS)is the pathologic basis of cardiac cerebro vascular diseases.In the past,there were mainly 3 theories,including lipidose deposition,injury repair and thrombogenesis,to explain the forming of AS.On basis of these theories,factors such as aging,hyperlipemia,hypertension,hyperglycaemia, hypercysteinemia and high blood uric acid are termed as high risks of CHD because they may induce blood vessel endothelium injury and lipidose deposition.Some progresses have been made in prevention of the genesis and advancement of AS by getting rid of or controlling of these high risks.However,people are beginning to question the effects of the preventions and treatments on these high risks for that the morbility age of CHD are younger than ever before,and the progress of AS speeds up. With the terming of ACS on acute progress stages of CHD,People re-recognized the pathologic and pathophysiologic characteristics of CHD in their developmental stages. Studies on AS found that unstable plaques are the pathological basis of ACS.The interventions of the inflammatory cells and immunocells to unstable plaques are key factors that leading to the instability and easily rupture of AS plaques.It is considered that systemic activation of the inflammatory factors and inflammatory reactions exist in ACS cases.What's more,people found that immunocells involve in all the AS developmental stages.They had proposed a new point of view that CHD is a process of chronic inflammation and a disease of autoimmunity.It is considered that inflammatory reactions and immune reactions induced by endogenous and exogenous risks are the pathological basis of AS.
Dendritic cells(DCs)are the most powerful specific antigen presenting cells that play a role of presenting antigens in the immunologic process.Minor DCs may intensively activate T cells,which may initiate the specific cellular immunity reaction. Their capacities of T cells activation are as 100-1000 folds as that of macrophages. They play an important role in the induction and regulation of immunologic response. It is confirmed by recent studies that arterial wall may offer a good microenviroment to the immunological reactions.A Vascular-associated lymphoid tissue(VALT)that similar to mucous membrane-associated lymphoid tissue in respiratory tract and gastrointestinal tract,exist in the normal endarterium.Some cell masses which are comprised of immunological competent cells and antigen presenting cells distribute diffusedly in these tissues.They may monitor and screen the potential endogeneous or exogenous harmful antigens in the vascular tissues.Vascular dendritic cells(VDCs) can be found in VALT.Normally speaking,only a very small number of VDCs which in an immature form,can be found in the vessel tunica intima and tunica adventitia. Aggregation of VDCs in the affected regions increase and,they always aggregate with T cells and macrophages in the inflammatory infilitrated regions.People presume that DCs may play a role in initiating inflammatory and immunological reactions in the genesis and development of AS for that DCs co-emerge with T cells in the weak affected regions.Recent studies showed that oxidated LDL and nicotine may promote the advancement of AS by activating DCs-mediated acquired immunological reactions.This suggest that DCs may play a role in the pathogenesis of AS and that they may play an important role in the regulation of the triggering and amplification of inflammatory and immunological reactions in AS.
Astragalus polysaccharids,one of the most important natural active ingredients in Astragalus,have the function of bi-directional regulation of blood sugar,promoting immunity,enhancing macrophage activity and promoting the transformation of lymphocyte,activating T cells,B cells and promoting the formation of antibodies in order to fight against various viral and bacterial diseases.In addition,the study found that APS play an important role in various diseases,for instance,APS have anti-tumor effect,but APS can not inhibit effectively the growth of tumor cells in vitro, suggesting that its anti-tumor effects of APS may be associated with immune effects. APS can reduce the incidence of type 1 diabetes of the non-obese mice significantly, and protect the the ultrastructure of pancreatic islets,restore the balance between Th1 cells and Th2 cells.APS can reduce NF-kB mRNA expression levels in the renal cortex of SD rats,enhance the expression of IkB mRNA,and can control the progress of diabetic nephropathy effectively.APS can inhibit metal-induced oxidative stress and renal ischemia-reperfusion injury,stimulate the immune regulation,inhibit glomerular mesangial cell proliferation and matrix synthesis,as well as reduced the expression ofβ1 integrin in mesangial cell.In relation with the research of cardiovascular disease,APS can reduce total cholesterol,apolipoprotein H, low-density lipoprotein level of healthy people effectively,as well as triglycerides levels in more than 50-year-old middle-aged healthy population.On the study of the hamster model of diabetic cardiomyopathy,APS exert the effect of anti-diabetic cardiomyopathy by inhibiting the chymotrypsin-AngⅡsystem.Besides,more studies have shown that astragalus polysaccharide increase the content of cAMP in platelets and inhibit platelet aggregation and thrombosis through the inhibition of platelet calmodulin and phosphodiesterase activity.Moreover,Astragalus Polysaccharides are one of the major components in Astragalus injection,and in the treatment of angina pectoris,Astragalus injection can reduce the number of angina attacks,extend the attack time interval,improve the clinical efficacy significantly. Above all,Astragalus injection intervening in the development of CHD may be related to the immune regulation function of APS.
Considering that DCs are key in natural defense and acquired immune and closely related to the occurrence and development of CHD,so in the treatment of CHD,whether APS play a role in regulating immune function though exerting on DCs?After treatment with APS,how the DCs functional status in antigen-presenting, and whether affect secretion of the functional proteins and immunomodulatory molecules,and the gene expression of these proteins in DCs or not.Study on genetic changes of DCs is the key in resolving these problems.
Our studies can mainly be divided into 3 portions.Peripheral blood mononuclear cell(PBMC)and serum abstracted from clinical cases are the objectives of our study.The gene expressions and functional changes of PBMC derived DCs after treatment with APS is the starting point in our study.Through immunofluorescence,flow cytometry,DNA microarray,RT-PCR and ELISA,we have focused on the relationship between the occurrence and development of AS and mature status,immune function and other gene expression differences of PBMC peripheral blood-derived DCs after APS treatment,and discussed deeply the status and the role of antigen-presenting cell function after treatment with APS in the treatment of AS.Aiming to provide an experimental evidence and target of immune therapy for the immune-mediated hypothesis in the development of AS,and review new theoretical platform and technical mean for the prevention and treatment of cardio-cerebrovascular disease,this study have the long-term economic value and important social significance.The results are as follows:
1.DCs derived from peripheral blood in a mature state after APS treatment,have the ability to induce T cell proliferation.
1.1 Culture and identification of DCs
In cultured 2 day,cells adhesion to the bottom of polystyrene bottle in the control group,part cells are suspended growth in medium in the experimental group, smaller,and no significant difference shape.In cultured 6 day,cells adhesion to the culture bottle bottom with round or oval in shape in control group;cells,showing suspended growth in medium,part of them aggregation in clusters,dendritic-like protrusionsin on cell surface in different quatity and shape,have the best growth status in LPS group,100mg/L group.Large number of vacuoles-like structure in the majority of the cytoplasm cell,collapsed cells,and a large number of atypical cell debris can be seen in 200mg/L APS group.In APS 100mg/L group,the phenotype of human peripheral blood PBMC derived DCs are CD1α~+,CD80~+,CD83~(low),CD86~+, HLA-DR~+by flow cytometry analysis.
1.2 Detection cytokine IL-12 in cultured supernatant.
Because of a large number of apoptotic cells in 200mg/L,the control group,LPS group,50mg/L APS group,100mg/L APS have been chosed to detect the cytokine IL-12 in cell supernatant.In culture 6 days,the content of IL-12 have significantly statistical difference in 4 groups of cells cultured supernatant(P=0.000);compared the content of IL-12 in cells cultured supernatant of LPS group,l00mg/L APS with the control group,50mg/L APS group,there have significantly statistical difference (P=0.000),and the content of IL-12 in cells cultured supernatant in the fomer two groups significantly higher than in the latter two groups.
1.3 The phenotype of peripheral blood PBMC derived DCs varied in each group.
Because of a large number of apoptotic cells in 200mg/L,the control group,LPS group,50mg/L APS group,l00mg/L APS have been chosed to detect the phenotype of peripheral blood PBMC derived DCs varied in each group.There have statistical difference in CD1α,CD86 of DCs phenotype between l00mg/L APS group,LPS group and control group,50mg/L APS group(P＜0.05),and the CD 1α,CD86 of DCs phenotype in l00mg/L APS group,LPS group Showed up-regulated expression;there have statistical difference in HLA-DR of DCs phenotype between LPS group and 50mg/L APS group(P＜0.05),and the HLA-DR of DCs phenotype in 50mg/L APS group Showed up-regulated expression.
1.4 Allogenic mixed lymphocytic reactions in PBMC derived DCs in each group. There have a significant difference ~3H-TDR incorporation rate in 4 groups(P＜0.01).At the proportion of 1:50,1:20 of DCs mixed with T lymphocytes,there have significantly statistical difference between l00mg/L APS group,LPS group and other two groups in the rate of H-TDR incorporation(P＜0.01),and the rate of H-TDR incorporation in l00mg/L APS group,LPS group significantly higher than the other two groups;but there have no statistical difference between the control group and 50mg/L in the ~3H-TDR incorporation rate(P＞0.05)
2 Detection different gene expression of the peripheral blood PBMC derived DCs by gene chip
The result of gene chip detection show that,the expression gene of functional protein after APS treatment in peripheral blood DCs have seven genes increased markedly,they are CD36,IGSF6,IL27,INHA,LIPA,MAP4K3 and SOD2,and belong to antigen recognition receptors,cytokine,cell enzymes and cell signal transduction system.And 26 genes showed decreased expression,they are ADAM19, ADAR,BASP1,BTG1,CCR7,CD40LG,CST7,CXCL9,CXCR4,DCTN2,EBB, ISG15,ICAM1,IFI16,IL15,ISG20,CD207,LTA,MARCKS,MARCKSL1, NFKB1,NFKB2,PNRC1,RAC1,RELB and TNFRSF11B,and belong to cell enzymes,antigen recognition receptors,cytokine receptor,cytokine and cellular signal transduction systems.The peripheral blood PBMC after APS treatment are reduced in the expression of cell adhesion and chemotactic migration of DCs receptors and related proteins such as AD AM19,CCR7,CD40LG,CST7,CXCL9 and CXCR4;the gene expression with related to the induction of cell proliferation and activation signal transduction pathway and functional protein are also decreased, such as ADAR,BASP1,BTG1,DCTN2,ISG15,ISG20,MARCKS,MARCKSL1, NFKB1,NFKB2,PNRC1,RAC1,RELB and TNFRSF11B;and the gene expression with related to antigen-presenting and immune response related protein are decreased, such as EBI3,IFI16,IL15,CD207,and LTA.In upregulated expression genes,there have antigen-binding protein gene such as CD36,digestion and degradation of antigen related cell and lysosome protein gene such as LIPA and SOD2,as well as inhibition inflammation and immune responses protein gene expression such as IL27 and INHA.
3 Detection the results of gene chip by fluorescence quantitative PCR showed that gene chip have better credibility in detection DCs gene.
Application fluorescence quantitative PCR in detection of microarray gene expression of CD36 and IL-27,as well as down-regulated expression gene FIF16 showed that,compared with control group,CD36 and IL-27 gene expression in DCs group after APS treatment increased width,FIF16 gene expression decreased width is similar with gene chip detection.
Through above three-part experiment,we can draw the conclusions as follows:
①The phenotype expression in peripheral blood DCs after APS treatment are in a mature state;
②The levels IL-12 secreted in peripheral blood PBMC derived DCs after APS treatment,are significantly higher than the control group,and have the ability to induce allogenic lymphocytic proliferation;
③The expression gene of functional protein after APS treatment in peripheral blood DCs have seven genes increased markedly,they are CD36,IGSF6,IL27,INHA, LIPA,MAP4K3 and SOD2,and belong to antigen recognition receptors,cytokine, cell enzymes and cell signal transduction system.And 26 genes showed significant decreased expression,they are ADAM19,ADAR,BASP1,BTG1,CCR7,CD40LG, CST7,CXCL9,CXCR4,DCTN2,EBI3,ISG15,ICAM1,IFI16,IL15,ISG20,CD207, LTA,MARCKS,MARCKSL1,NFKB1,NFKB2,PNRC1,RAC1,RELB and TNFRSF11B,and belong to cell enzymes,antigen recognition receptors,cytokine receptor,cytokine and cellular signal transduction systems.
④Detection the CD36 and IL-27 gene which upregulated expression,and IFI16 gene which downregulated expression in microarray by fluorescence quantitative PCR,verified the results of the gene microarray.
引文
[1]Steinman RM,Adams JC,Cohn ZA.Identification of a novel cell type in peripheral lymphoid organs of mice.Ⅳ.Identification and distribution in mouse spleen[J].J Exp Med.1975,141(4):804-820.
[2]Ariel Savina,Sebastian Amigorena.Phagocytosis and antigen presentation in dendritic cells[J].Immunol Rev,2007,219:143-156.
[3]S Ranjit,L Dazhu.Potential role of dendritic cells for progression of atheroscleroticlesions[J].Postgrad Med J,2006,82(971):573-575.
[4]Gwendalyn J.Randolph,Jordi Ochando,Santiago Partida-S(?)nchez.Migration of Dendritic Cell Subsets and their Precursors[J].Annu Rev Immunol,1991,271-296.
[5]Li Jin,Bao Yixi,Lam Waikei,Li Wenwen,et al.Immunoregulatory and Anti-Tumor Effects of Polysaccharopeptide and Astragalus polysaccharides on Tumor-Bearing Mice[J].Immunppharmacol Immunotoxicol,2008,30(4):771-782.
[6]张海澄,郭继鸿.冠心病流行病学与一级预防[J].中国实用内科杂志,2002,22(8):449-451.
[7]Falk E.Pathogenesis of atherosclerosis.J Am Coil Cardiol,2006,47:C7-12.
[8]Ross RS.Ischemic heart disease:an overview.Am J Cardiol,1975,36:496-505.
[9]Goldstein JL,Brown MS.Lipoprotein receptors,cholesterol metabolism,and atherosclerosis.Arch Pathol,1975,99:181-4.
[10]Steinbaugh M,Strong WB.Primary prevention of atherosclerosis:nutritional aspects.South Med J,1975,68:328-34.
[11]Eric J.Wasserman,Neal M.Shipley.Atherothrombosis in acute coronary syndromes:mechanisms,markers,and mediators of vulnerability[J].Mt Sinai Med,2006,73(1):431-439.
[12]Insull W Jr.The pathology of atherosclerosis:plaque development and plaque responses to medical treatment[J].Am J Med,2009,122(1 Suppl):S3-S14.
[13]Israel Gotsman,Arlene H.Sharpe,Andrew H.Lichtman.T-Cell Costimulation and Coinhibition in Atherosclerosis[J].Cir Res,2008,103:1220-1231.
[14]GriendIing KK,Harrison DG:Out,damned not:studies of the NAPDH oxidase in atheroslosis[J]J Clin Invest,2001,108(10):1423-1424.
[15]Hansson GK,Libby P,Schonbeck U,et al.Innate and adaptive immunity in the pathogenesis of atherosclerosis [J].Cir Res,2002,91(4):281-291.
[16]Binder CJ,Chang MK,Shaw PX,et al.Innate and acquired immunity in atherogenesis[J].Nat Med,2002,8(11):1218-26.
[17]Ralph M.Steinman,Daniel Hawiger,Michel C.Nussenzweig.Tolerogenic dendritic cells,Annu Rev Immunol,2003,21:685-711.
[18]Foti M,Granucci F,Pelizzola M,et al.Dendritic cells in pathogen recognition and induction of immune responses:a functional genomics approach.J Leukoc Biol,2006,79:913-6.
[19]Kubach J,Becker C,Schmitt E,et al.Dendritic cells:sentinels of immunity and tolerance.Int J Hematol,2005,81:197-203.
[20]Li YP,Latger-Canard V,Marchal L,et al.The regulatory role of dendritic cells in the immune tolerance.Biomed Mater Eng,2006,16:S 163-70.
[21]Niess JH,Reinecker HC.Lamina propria dendritic cells in the physiology and pathology of the gastrointestinal tract.Curr Opin Gastroenterol,2005,21:687-91.
[22]Bailey M,Haverson K,Inman C,et al.The influence of environment on development of the mucosal immune system.Vet Immunol Immunopathol,2005,108:189-98.
[23]Ralph M.Steinman.The Dendritic Cell System and its Role in Immunogenicity[J].Annu Rev Immunol,1991,9:271-296.
[24]A.Yilmaz, M.Lochno, F.Traeg, et al.Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques[J].Atherosclerosis,176:101-110.
[25]Kawahara I,Kitagawa N,Tsutsumi K,et al.The expression of vascular dendritic cells in human atherosclerotic carotid plaques[J].Hum Pathol,2007,38(9):1378-1385.
[26]Douglas P Zipes,Peter Lbby,Eugene Braunwald,陈灏珠.Braunwald心脏病学[M],北京:人民卫生出版社,2007:867-881.
[27]吕永恒,李志,刘映峰,等.冠心病患者树突状细胞的功能及依那普利干预效应[J].高血压杂志,2006,14(16):442-445.
[28]Wang L,Li D,Yang K,Hu Y,et al.Toll-like receptor-4 and mitogen-activated protein kinase signal system are involved in activation of dendritic cells in patients with acute coronary syndrome[J].Immunol,2008,125(1):122-30.
[29]Hongyu Shi,Junbo Ge,Weiyi Fang,et al.Peripheral-blood dendritic cells in men with coronary heart disease[J],Am J Cardiol,2007,100:593-597.
[30]雷正一.黄芪在心血管系统疾病中的作用[J].中国中西医结合杂志,1993,13(7):443.
[31]徐军,黄象娟,齐法莲,等.洛泰和黄芪注射液对冠心病患者血浆中ET-1和vWF的影响[J].中国免疫学杂志,2003,19:128.
[32]薛呼建,高凤荣,马爱根,等.黄芪注射液对冠心病患者血糖、胰岛素和血脂的影响[J].中国综合临床,2003,19(12):1074-1075.
[33]姚萍,雷艳蓉,唐恩东.黄芪注射液治疗冠心病心绞痛的临床观察[J].四川中医,2004,22(7):52-53.
[34]周淑英,卢振初,王佾先,等.黄芪多糖(APS)抗肿瘤作用的实验研究[J].药物生物技术,1995,2(2):22-25.
[35]Chen W,Yu,M.Effects of astragalus polysaccharide on gene expression profiles in islets of NOD mice with microarray technique.Chinese Journal of Endocrinology and Metabolism,2004,20(6),545-548.
[36]Ying-Wen Zhang,Chao-Yan Wu a,Juei-Tang Cheng.Merit of Astragalus polysaccharide in the improvement of early diabetic nephropathy with an effect on mRNA expressions of NF-κB and IrκB in renal cortex of streptozotoxin-induced diabetic rats[J].J Ethnopharm,2007,114:387-392.
[37]Yuan C.H,Liu Y.F,Cheng Y.Experimental study on effect of Astragalus extractum on canine isolated kidney during hypothermia perfusion and preservation[J].Zhongguo Zhong Xi Yi Jie He Za Zhi,2003,23:291-293.
[38]尹俊青,宋淑珍,田亚平,等.黄芪多糖对健康人群血脂水平的干预效应[J].中国临床康复,2005,9(3 1):160-161.
[39]Wei Chena,Yi-Ming Lib,Mao-Hua Yua.Astragalus polysaccharides inhibited diabetic cardiomyopathy in hamsters depending on suppression of heart chymase activation[J].J Diabetes Complications,2009.
[40]宗秀芝,于晶.黄芪治疗心血管疾病的作用机理[J].吉林中医药,2008,28(8):600-601.
[41]Steinman RM.The dendritic cell system and its role in immunogenicity[J].Annu Rev Immunol,1991,9:271-296.
[42]Erwin F.Strasser,Benjamin Keller,Martin Hendelmeier,et al.Short-term liquid storage of CD14+monocytes,CD1 lc+,and CD123+precursor dendritic cells produced by leukocytapheresis[J].Transfusion,2007,47(7):1241-1249.
[43]Xu H,Kramer M,Spengler HP,et al.Dendritic cells differentiated from human monocytes through a combination of IL-4,GM-CSF and IFN-gamma exhibit phenotype and function of blood dendritic cells[J].Adv Exp Med Biol,1995,378:75-8
[44]张玉梅,孙桂芝,周同,等.体外培养人树突状细胞分化成熟特性分析[J].中国微循环,2006,10(1):9-11.
[45]Guinet E,Yoshida K,Nouri-Shirazi M.Nicotinic environment affects the differentiation and functional maturation of monocytes derived dendritic cells [J].Immunol Lett.2004 Aug 15;95(1):45-55.
[46]Wang H,Huang H,Cai KY.The effect of oxidized low-density lipoprotein on the maturation and its immune function of monocyte-derived dendritic cells[J].Zhonghua Xin Xue Guan Bing Za Zhi.2008 Dec;36(12):1106-1109.
[47]冯刚,李胜富,李幼平,等.反义肽核酸对树突状细胞CD86表达的抑制作用[J].华西医大学报,2002,33(2):192-195.
[48]Peng Shao,Lu-Hang Zhao,Zhi-Chen,et al.Regulation on maturation and function of dendritic cells by Astragalus mongholicus polysaccharides[J].Int Immunopharmacol,2006,6:1161-1166.
[49]姚莉,梁晓俐,王德文.树突细胞的凋亡与调控[J].免疫学杂志,2003,19(3):96-99.
[50]Banchereau J,Steinman R M.Dendritic cells and the control of immunity[J].Nature,1998,392:245-252.
[1]Sheikine YA,Hansson GK.Chemokines as potential therapeutic targets in atherosclerosis.Curr Drug Targets,2006,7:13-27.
[2]Hallenbeck JM,Hansson GK,Becker KJ.Immunology of ischemic vascular disease:plaque to attack.Trends Immunol,2005,26:550-6.
[3]Falk E.Pathogenesis of atherosclerosis.J Am Coll Cardiol,2006,47:C7-12.
[4]Achar SA,Kundu S,Norcross WA.Diagnosis of acute coronary syndrome.Am Fam Physician,2005,72:119-26.
[5]Large GA.Contemporary management of acute coronary syndrome.Postgrad Med J,2005,81:217-22.
[6]Shen CX,Chen HZ,Ge JB.The role of inflammatory stress in acute coronary syndrome.Chin Med J (Engl),2004,117:133-9.
[7]Prasad A, Mathew V, Holmes DR Jr, et al.Current management of non-ST-segment-elevation acute coronary syndrome:reconciling the results of randomized controlled trials.Eur Heart J,2003,24:1544-53.
[8]Corrado E,Rizzo M,Tantillo R,et al.Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions:a 5-year follow-up study.Stroke,2006,37:482-6.
[9]Ford PJ,Gemmell E,Timms P,et al.Anti-P.gingivalis response correlates with atherosclerosis.J Dent Res,2007,86:35-40.
[10]Ausiello CM,Palazzo R,Spensieri F,et al.60-kDa heat shock protein of Chlamydia pneumoniae is a target of T-cell immune response.J Biol Regul Homeost Agents,2005,19:136-40.
[11]Mandal K,Foteinos G,Jahangiri M,et al.Role of antiheat shock protein 60 autoantibodies in atherosclerosis.Lupus,2005,14:742-6.
[12]Fields ML,Nish SA,Hondowicz BD,et al.The influence of effector T cells and Fas ligand on lupus-associated B cells.J Immunol,2005,175:104-11.
[13]Shibata Y,Ohata H,Yamashita M,et al.Immunologic response enhances atherosclerosis-type 1 helper T cell (Thl)-to-type 2 helper T cell (Th2) shift and calcified atherosclerosis in Bacillus Calmette-Guerin(BCG)-treated apolipoprotein E-knockout (apo E-/-) mice.Transl Res,2007,149:62-9.
[14]Hansson GK,Berne GP.Atherosclerosis and the immune system.Acta Paediatr Suppl,2004,93:63-9.
[15]Wick G,Schett G,Amberger A,et al.Is atherosclerosis an immunologically mediated disease?.Immunol Today,1995,16:27-33.
[16]Kaiser J.Genomics.Celera to end subscriptions and give data to public GenBank.Science,2005,308:775.
[17]Temple G,Lamesch P,Milstein S,et al.From genome to proteome:developing expression clone resources for the human genome.Hum Mol Genet,2006,15 Spec No 1:R31-43.
[18]Boyce JD,Adler B.How does Pasteurella multocida respond to the host environment?.Curr Opin Microbiol,2006,9:117-22.
[19]Deutsch S,Reymond A.The future is genome-wide.Genome Biol,2006,7:324.
[20]Kane MD.Technical issues in DNA microarray production and utilization:impact on clinical research.Expert Rev Mol Diagn,2005,5:649-54.
[21]Bracken MB.Genomic epidemiology of complex disease:the need for an electronic evidence-based approach to research synthesis.Am J Epidemiol,2005,162:297-301.
[22]Boguski MS.ENCODE and ChIP-chip in the genome era.Genomics,2004,83:347-8.
[23]Slater EP,Diehl SM,Langer P,et al.Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors.Eur J Endocrinol, 2006,154:587-98.
[24]Feng HC,Tsao SW,Ngan HY,et al.Differential gene expression identified in complete hydatidiform mole by combining suppression subtractive hybridization and cDNA microarray.Placenta,2006,27:521-6.
[25]Piepho HP.Optimal allocation in designs for assessing heterosis from cDNA gene expression data.Genetics,2005,171:359-64.
[26]Ylstra B,van den Ijssel P,Carvalho B,et al.BAC to the future! or oligonucleotides:a perspective for micro array comparative genomic hybridization(array CGH).Nucleic Acids Res,2006,34:445-50.
[27]Loy A,Bodrossy L.Highly parallel microbial diagnostics using oligonucleotide microarrays.Clin Chim Acta,2006,363:106-19.
[28]Brandt O,Hoheisel JD.Peptide nucleic acids on microarrays and other biosensors.Trends Biotechnol,2004,22:617-22.
[29]Zabel BA,Silverio AM,Butcher EC.Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood.J Immunol,2005,174:244-51.
[30]Moutaftsi M,Brennan P,Spector SA,et al.Impaired lymphoid chemokine-mediated migration due to a block on the chemokine receptor switch in human cytomegalovirus-infected dendritic cells.J Virol,2004,78:3046-54.
[31]Chieppa M,Bianchi G,Doni A,et al.Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program.J Immunol,2003,171:4552-60.
[32]Riol-Blanco L,Sanchez-Sanchez N,Torres A,et al.The chemokine receptor CCR7 activates in dendritic cells two signaling modules that independently regulate chemotaxis and migratory speed.J Immunol,2005,174:4070-80.
[33]张新华,钟翠平.树突状细胞与趋化因子的研究进展.解剖学杂志,2004.27 (1):93-96.
[34]孟哲峰.树突状细胞来源的趋化因子的免疫调节作用研究进展.国外医学.临床生物化学与检验学分册,2004.25(1):65-66,69.
[35]Yilmaz A,Weber J,Cicha I,et al.Decrease in circulating myeloid dendritic cell precursors in coronary artery disease.J Am Coll Cardiol,2006,48:70-80.
[36]Bauriedel G,Skowasch D,Welsch U,et al.Role of dendritic cells in specific atherosclerosis types.Eur Heart J,2006,27:116;author reply 116-7.
[37]De Palma R,Del Galdo F,Abbate G,et al.Patients with acute coronary syndrome show oligoclonal T-cell recruitment within unstable plaque:evidence for a local,intracoronary immunologic mechanism.Circulation,2006,113:640-6.
[38]李大主,Ranjit S,曾秋棠,等.老年急性冠状动脉综合征患者树突状细胞的功能状态.中华老年心脑血管病杂志.2004,6(5):308-310.
[39]李大主,Sharma Ranjit,曾秋棠,等.不稳定型心绞痛患者树突状细胞功能的研究.中国病理生理杂志.2005,21(4):732-732,737.
[40]Ranjit S,Dazhu L,Qiutang Z,et al.Differentiation of dendritic cells in monocyte cultures isolated from patients with unstable angina.Int J Cardiol,2004,97:551-5.
[41]Wu L,Dakic A.Development of dendritic cell system.Cell Mol Immunol,2004,1:112-8.
[42]Quah BJ,O'Neill HC.Maturation of function in dendritic cells for tolerance and immunity.J Cell Mol Med,2005,9:643-54.
[43]Doni A,Michela M,Bottazzi B,et al.Regulation of PTX3,a key component of humoral innate immunity in human dendritic cells:stimulation by IL-10 and inhibition by IFN-gamma.J Leukoc Biol,2006,79:797-802.
[44]Hasan U,Chaffois C,Gaillard C,et al.Human TLR10 is a functional receptor,expressed by B cells and plasmacytoid dendritic cells,which activates gene transcription through MyD88.J Immunol,2005,174:2942-50.
[45]Jin Y,Fuller L,Ciancio G,et al.Antigen presentation and immune regulatory capacity of immature and mature-enriched antigen presenting(dendritic)cells derived from human bone marrow.Hum Immunol,2004,65:93-103.
[46]Regnault A,Lankar D,Lacabanne V,et al.Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization.J Exp Med,1999,189:371-80.
[47]Tanaka Y,Mamalaki C,Stockinger B,et al.In vitro negative selection of alpha beta T cell receptor transgenic thymocytes by conditionally immortalized thymic cortical epithelial cell lines and dendritic cells.Eur J Immunol,1993,23:2614-21.
[48]Coates PT,Colvin BL,Ranganathan A,et al.CCR and CC chemokine expression in relation to Flt3 ligand-induced renal dendritic cell mobilization.Kidney Int,2004,66:1907-17.
[49]Yamagami S,Hamrah P,Miyamoto K,et al.CCR5 chemokine receptor mediates recruitment of MHC class Ⅱ-positive Langerhans cells in the mouse corneal epithelium.Invest Ophthalmol Vis Sci,2005,46:1201-7.
[50]Dewin DR,Catusse J,Gompels UA.Identification and characterization of U83A viral chemokine,a broad and potent beta-chemokine agonist for human CCRs with unique selectivity and inhibition by spliced isoform.J Immunol,2006,176:544-56.
[51]Zhang Y,Yoneyama H,Wang Y,et al.Mobilization of dendritic cell precursors into the circulation by administration of MIP-1alpha in mice.J Natl Cancer Inst,2004,96:201-9.
[52]陈兴国,池淑红,顾越英等.系统性红斑狼疮相关基因IFIT1的功能初探.中华风湿病学杂志,2004,8(7):395-399.
[53]徐祖森 周映.IFI16及其信号转导途径在系统性红斑狼疮发病中的作用.中华皮肤科杂志.2006,39(9):524-526.
[54]Kubach J,Becker C,Schmitt E,et al.Dendritic cells:sentinels of immunity and tolerance.Int J Hematol,2005,81:197-203.
[55]Hochweller K,Sweenie CH,Anderton SM.Immunological tolerance using synthetic peptides--basic mechanisms and clinical application.Curr Mol Med,2006,6:631-43.
[56]Li YP,Larger-Canard V,Marchal L,et al.The regulatory role of dendritic cells in the immune tolerance.Biomed Mater Eng,2006,16:S 163-70.
[1]Parashar D,Chauhan DS,Sharma VD,et al.Applications of real-time PCR technology to mycobacterial research.Indian J Med Res,2006,124:385-98.
[2]Honest H,Sharma S,Khan KS.Rapid tests for group B Streptococcus colonization in laboring women: a systematic review.Pediatrics,2006,117:1055-66.
[3]Espy MJ,Uhl JR,Sloan LM,et al.Real-time PCR in clinical microbiology:applications for routine laboratory testing.Clin Microbiol Rev,2006,19:165-256.
[4]Suzuki N,Yoshida A,Nakano Y.Quantitative analysis of multi-species oral biofilms by TaqMan Real-Time PCR.Clin Med Res,2005,3:176-85.
[5]Overbergh L,Giulietti A,Valckx D,et al.The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression.J Biomol Tech,2003,14:33-43.
[6]Giulietti A,Overbergh L,Valckx D,et al.An overview of real-time quantitative PCR: applications to quantify cytokine gene expression.Methods,2001,25:386-401.
[7]Valasek MA,Repa JJ.The power of real-time PCR.Adv Physiol Educ,2005,29:151-9.
[8]Jones SW,Dobson ME,Francesconi SC,et al.DNA assays for detection,identification,and individualization of select agent microorganisms.Croat Med J,2005,46:522-9.
[9]Bustin SA,Benes V,Nolan T,et al.Quantitative real-time RT-PCR--a perspective.J Mol Endocrinol,2005,34:597-601.
[10]Wang XS,Simmons Z,Liu W,et al.Differential expression of genes in amyotrophic lateral sclerosis revealed by profiling the post mortem cortex. Amyotroph Lateral Scler,2006,7:201-10.
[11]Boyer J,Allen WL,McLean EG,et al.Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer.Cancer Res,2006,66:2765-77.
[12]Wong LJ,Bai RK.Real-time quantitative polymerase chain reaction analysis of mitochondrial DNA point mutation.Methods Mol Biol,2006,335:187-200.
[13]Luthra R,Medeiros LJ.TaqMan reverse transcriptase-polymerase chain reaction coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type.Methods Mol Biol,2006,335:135-45.
[14]Elsayed S,Plewes K,Church D,et al.Use of molecular beacon probes for real-time PCR detection of Plasmodium falciparum and other Plasmodium species in peripheral blood specimens.J Clin Microbiol,2006,44:622-4.
[15]Gubala AJ,Proll DF.Molecular-beacon multiplex real-time PCR assay for detection of Vibrio cholerae.Appl Environ Microbiol,2006,72:6424-8.
[16]Sinsimer D,Leekha S,Park S,et al.Use of a multiplex molecular beacon platform for rapid detection of methicillin and vancomycin resistance in Staphylococcus aureus.J Clin Microbiol,2005,43:4585-91.
[17]Yang ZZ,Habib M,Shuai JB,et al.Detection of PCV2 DNA by SYBR Green I-based quantitative PCR.J Zhejiang Univ Sci B,2007,8:162-9.
[18]Kohdera U,Kino M,Ito M.Detection of adenovirus DNA in throat swabs and blood by SYBR green real-time PCR assay in patients with adenovirus-associated tonsillitis.Jpn J Infect Dis,2006,59:394-6.
[19]Ivyna Bong PN,Patricia L,Pauline B,et al.Quantitative analysis of the expression of p53 gene in colorectal carcinoma by using real-time PCR.Trop Biomed,2006,23:53-9.
[20]Feng JL,Chen SN,Tang XS,et al.Quantitative determination of cucumber mosaic virus genome RNAs in virions by real-time reverse transcription-polymerase chain reaction.Acta Biochim Biophys Sin (Shanghai),2006,38:669-76.
[21]Gomes AL,Melo FL,Werkhauser RP,et al.Development of a real time polymerase chain reaction for quantitation of Schistosoma mansoni DNA.Mem Inst Oswaldo Cruz,2006,101 Suppl 1:133-6.
[22]Mata JF,Scrideli CA,Queiroz RP,et al.Cytosine arabinoside-metabolizing enzyme genes are underexpressed in children with MLL gene-rearranged acute lymphoblastic leukemia.Braz J Med Biol Res,2006,39:1417-23.
[23]Morey JS,Ryan JC,Van Dolah FM.Microarray validation:factors influencing correlation between oligonucleotide microarrays and real-time PCR.Biol Proced Online,2006,8:175-93.
[24]Christensen DR,Hartman LJ,Loveless BM,et al.Detection of biological threat agents by real-time PCR:comparison of assay performance on the R.A.P.I.D,the LightCycler,and the Smart Cycler platforms.Clin Chem,2006,52:141-5.
[25]Yu Z,Michel FC Jr,Hansen G,et al.Development and application of real-time PCR assays for quantification of genes encoding tetracycline resistance.Appl Environ Microbiol,2005,71:6926-33.
[26]Yang YH,Nam MS,Yang ES.Rapid prenatal diagnosis of trisomy 21 by real-time quantitative polymerase chain reaction with amplification of small tandem repeats and S100B in chromosome 21.Yonsei Med J,2005,46:193-7.
[27]Cui W,Taub DD,Gardner K.qPrimerDepot:a primer database for quantitative real time PCR.Nucleic Acids Res,2007,35:D805-9.
[28]Moriya Y,Nakamura T,Okamura N,et al.Comparison of synthetic DNA templates with authentic cDNA templates in terms of quantification by real-time quantitative reverse transcription polymerase chain reaction.Biol Pharm Bull, 2006,29:535-8.
[29]Brettar I,Labrenz M,Flavier S,et al.Identification of a Thiomicrospira denitrificans-like epsilonproteobacterium as a catalyst for autotrophic denitrification in the central Baltic Sea.Appl Environ Microbiol,2006,72:1364-72.
[30]Dussault AA,Pouliot M.Rapid and simple comparison of messenger RNA levels using real-time PCR.Biol Proced Online,2006,8:1-10.
[31]Zheng Y,Josefowicz SZ,Kas A,et al.Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells.Nature,2007,445:936-40.
[32]Kobasa D,Jones SM,Shinya K,et al.Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus.Nature,2007,445:319-23.
[33]Redon R,Ishikawa S,Fitch KR,et al.Global variation in copy number in the human genome.Nature,2006,444:444-54.
[34]Baur JA,Pearson KJ,Price NL,et al.Resveratrol improves health and survival of mice on a high-calorie diet.Nature,2006,444:337-42.
[35]Mouchel CF,Osmont KS,Hardtke CS.BRX mediates feedback between brassinosteroid levels and auxin signalling in root growth.Nature,2006,443:458-61.
[36]Abzhanov A,Kuo WP,Hartmann C,et al.The calmodulin pathway and evolution of elongated beak morphology in Darwin's finches.Nature,2006,442:563-7.
[37]Gilchrist M,Thorsson V,Li B,et al.Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4.Nature,2006,441:173-8.
1.马文丽,郑文岭.DNA芯片技术的方法与应用[M].广州:广东科技出版社,2002:7-5359-3065-4.
2.Schena,M.Genome analysis with gene expression microarrays.BioEssays 18,427-431(1996).
3.Lockhart,D.J.et al.Expression monitoring by hybridization tohigh-densityoligonucleotide arrays.Nature Biotechnol.13,1675-1680(1996).
4.Southern,E.M.Blotting at 25.Trends Biochem.Sci.25,585-588(2000).
5.Wodicka,L.,Dong,H.,Mittmann,M.,Ho,M.H.& Lockhart,D.J.Genome-wideexpression monitoring in Saccharomyce cerevisiae.Nature Biotechnol.15,1359-1367(1997).
6.李凌,马文丽.DNA芯片技术研究进展[J].中国生物化学与分子生物学报,2000,16(2):151-155
7.Yuen,T.,Wurmbach,E.,Pfeffer,R.L.,Ebersole,B.J.& Sealfon,S.C.Accuracy andcalibration of commercial oligonucleotide and custom cDNA microarrays.NucleicAcids Res.30,e48(2002).
8.Schena,M.et al.Microarrays:biotechnology's discovery platform forfunctionalgenomics.Trends Biotechnol.16,301-306(1998).
9.Rose,D.Microfluidic technologies and instrumentation for printing DNA microarrays.in Microarray Biochip Technology 5th edn.(ed.Schena,M.)19-38Eaton Publishing,Natick,MA,2000).
10.Carr,D.B.,Somogyi,R.& Miehaels,G.Templates for looking at gene expressionelustering.Statistical Computing and Graphics Newsletter 8,20-29(1997).
11.Eisen,M.B.,Spellman,P.T.,Brown,P.O.& Botstein,D.Cluster analysis and displayof genome-wide expression patterns.Proc.Natl.Acad.Sci.USA 95,14863-14868 (1998).
12.Bjorkholm,B.et al.Comparison of genetic divergence and fitness between twosubclones of Helicobacter pylori.Infect.Immun.69,7832-7838 (2001).
13.Wang,D.,Liu,S.,Trummer,B.J.,Deng,C.& Wang,A.Carbohydrate microarraysfor the recognition of cross-reactive molecular markers of microbes and hostcells.Nature Biotechnol.20,275-281(2002).
14.DeRisi,J.L.,Iyer,V.R.& Brown,P.O.Exploring the metabolic and genetic controlof gene expression on a genomic scale.Science 278,680-686 (1997).
15.Heller,R.A.et al.Discovery and analysis of inflammatory disease-related genesusing cDNA microarrays.Proc.Natl.Acad.Sci.USA 94,2150-2155 (1997).
16.Robinl,.Stears,Todd Martinsky&Mark Schena,Trends in microarray analysis .Nature medicine,January 2003.
17.Xiong,M,Li,W.,Zhao,J.,Jin,L.& Boerwinkle,E.Feature (gene) selection ingene expression-based tumor classification.Mol.Genet.Metab.73,239-247(2001).
18.Selaru,F.M.et al.Artificial neural networks distinguish among subtypes of neoplasticcolorectal lesions.Gastroenterology 122,606-613 (2002).
19.MacBeath,G.& Schreiber,S.L.Printing proteins as microarrays for high-throughputfunction determination.Science 289,1760-1763 (2000).
20.Wilson,D.S.& Nock,S.Functional protein microarrays.Curr.Opin.Chem.Biol.6,81-85 (2002).21
21.Cao,Y.C.,Jin,R.& Mirkin,C.A.Nanoparticles with Raman spectroscopic fingerprintsfor DNA and RNA detection.Science 297,1536-1540 (2002).
22.Fodor,S.P.et al.Light-directed,spatially addressable parallel chemical synthesis.Science 251,767-773 (1991).
[2]Ariel Savina,Sebastian Amigorena.Phagocytosis and antigen presentation in dendritic cells[J].Immunol Rev,2007,219:143-156.
[3]S Ranjit,L Dazhu.Potential role of dendritic cells for progression of atheroscleroticlesions[J].Postgrad Med J,2006,82(971):573-575.
[4]Gwendalyn J.Randolph,Jordi Ochando,Santiago Partida-S(?)nchez.Migration of Dendritic Cell Subsets and their Precursors[J].Annu Rev Immunol,1991,271-296.
[5]Li Jin,Bao Yixi,Lam Waikei,Li Wenwen,et al.Immunoregulatory and Anti-Tumor Effects of Polysaccharopeptide and Astragalus polysaccharides on Tumor-Bearing Mice[J].Immunppharmacol Immunotoxicol,2008,30(4):771-782.
[6]张海澄,郭继鸿.冠心病流行病学与一级预防[J].中国实用内科杂志,2002,22(8):449-451.
[7]Falk E.Pathogenesis of atherosclerosis.J Am Coil Cardiol,2006,47:C7-12.
[8]Ross RS.Ischemic heart disease:an overview.Am J Cardiol,1975,36:496-505.
[9]Goldstein JL,Brown MS.Lipoprotein receptors,cholesterol metabolism,and atherosclerosis.Arch Pathol,1975,99:181-4.
[10]Steinbaugh M,Strong WB.Primary prevention of atherosclerosis:nutritional aspects.South Med J,1975,68:328-34.
[11]Eric J.Wasserman,Neal M.Shipley.Atherothrombosis in acute coronary syndromes:mechanisms,markers,and mediators of vulnerability[J].Mt Sinai Med,2006,73(1):431-439.
[12]Insull W Jr.The pathology of atherosclerosis:plaque development and plaque responses to medical treatment[J].Am J Med,2009,122(1 Suppl):S3-S14.
[13]Israel Gotsman,Arlene H.Sharpe,Andrew H.Lichtman.T-Cell Costimulation and Coinhibition in Atherosclerosis[J].Cir Res,2008,103:1220-1231.
[14]GriendIing KK,Harrison DG:Out,damned not:studies of the NAPDH oxidase in atheroslosis[J]J Clin Invest,2001,108(10):1423-1424.
[15]Hansson GK,Libby P,Schonbeck U,et al.Innate and adaptive immunity in the pathogenesis of atherosclerosis [J].Cir Res,2002,91(4):281-291.
[16]Binder CJ,Chang MK,Shaw PX,et al.Innate and acquired immunity in atherogenesis[J].Nat Med,2002,8(11):1218-26.
[17]Ralph M.Steinman,Daniel Hawiger,Michel C.Nussenzweig.Tolerogenic dendritic cells,Annu Rev Immunol,2003,21:685-711.
[18]Foti M,Granucci F,Pelizzola M,et al.Dendritic cells in pathogen recognition and induction of immune responses:a functional genomics approach.J Leukoc Biol,2006,79:913-6.
[19]Kubach J,Becker C,Schmitt E,et al.Dendritic cells:sentinels of immunity and tolerance.Int J Hematol,2005,81:197-203.
[20]Li YP,Latger-Canard V,Marchal L,et al.The regulatory role of dendritic cells in the immune tolerance.Biomed Mater Eng,2006,16:S 163-70.
[21]Niess JH,Reinecker HC.Lamina propria dendritic cells in the physiology and pathology of the gastrointestinal tract.Curr Opin Gastroenterol,2005,21:687-91.
[22]Bailey M,Haverson K,Inman C,et al.The influence of environment on development of the mucosal immune system.Vet Immunol Immunopathol,2005,108:189-98.
[23]Ralph M.Steinman.The Dendritic Cell System and its Role in Immunogenicity[J].Annu Rev Immunol,1991,9:271-296.
[24]A.Yilmaz, M.Lochno, F.Traeg, et al.Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques[J].Atherosclerosis,176:101-110.
[25]Kawahara I,Kitagawa N,Tsutsumi K,et al.The expression of vascular dendritic cells in human atherosclerotic carotid plaques[J].Hum Pathol,2007,38(9):1378-1385.
[26]Douglas P Zipes,Peter Lbby,Eugene Braunwald,陈灏珠.Braunwald心脏病学[M],北京:人民卫生出版社,2007:867-881.
[27]吕永恒,李志,刘映峰,等.冠心病患者树突状细胞的功能及依那普利干预效应[J].高血压杂志,2006,14(16):442-445.
[28]Wang L,Li D,Yang K,Hu Y,et al.Toll-like receptor-4 and mitogen-activated protein kinase signal system are involved in activation of dendritic cells in patients with acute coronary syndrome[J].Immunol,2008,125(1):122-30.
[29]Hongyu Shi,Junbo Ge,Weiyi Fang,et al.Peripheral-blood dendritic cells in men with coronary heart disease[J],Am J Cardiol,2007,100:593-597.
[30]雷正一.黄芪在心血管系统疾病中的作用[J].中国中西医结合杂志,1993,13(7):443.
[31]徐军,黄象娟,齐法莲,等.洛泰和黄芪注射液对冠心病患者血浆中ET-1和vWF的影响[J].中国免疫学杂志,2003,19:128.
[32]薛呼建,高凤荣,马爱根,等.黄芪注射液对冠心病患者血糖、胰岛素和血脂的影响[J].中国综合临床,2003,19(12):1074-1075.
[33]姚萍,雷艳蓉,唐恩东.黄芪注射液治疗冠心病心绞痛的临床观察[J].四川中医,2004,22(7):52-53.
[34]周淑英,卢振初,王佾先,等.黄芪多糖(APS)抗肿瘤作用的实验研究[J].药物生物技术,1995,2(2):22-25.
[35]Chen W,Yu,M.Effects of astragalus polysaccharide on gene expression profiles in islets of NOD mice with microarray technique.Chinese Journal of Endocrinology and Metabolism,2004,20(6),545-548.
[36]Ying-Wen Zhang,Chao-Yan Wu a,Juei-Tang Cheng.Merit of Astragalus polysaccharide in the improvement of early diabetic nephropathy with an effect on mRNA expressions of NF-κB and IrκB in renal cortex of streptozotoxin-induced diabetic rats[J].J Ethnopharm,2007,114:387-392.
[37]Yuan C.H,Liu Y.F,Cheng Y.Experimental study on effect of Astragalus extractum on canine isolated kidney during hypothermia perfusion and preservation[J].Zhongguo Zhong Xi Yi Jie He Za Zhi,2003,23:291-293.
[38]尹俊青,宋淑珍,田亚平,等.黄芪多糖对健康人群血脂水平的干预效应[J].中国临床康复,2005,9(3 1):160-161.
[39]Wei Chena,Yi-Ming Lib,Mao-Hua Yua.Astragalus polysaccharides inhibited diabetic cardiomyopathy in hamsters depending on suppression of heart chymase activation[J].J Diabetes Complications,2009.
[40]宗秀芝,于晶.黄芪治疗心血管疾病的作用机理[J].吉林中医药,2008,28(8):600-601.
[41]Steinman RM.The dendritic cell system and its role in immunogenicity[J].Annu Rev Immunol,1991,9:271-296.
[42]Erwin F.Strasser,Benjamin Keller,Martin Hendelmeier,et al.Short-term liquid storage of CD14+monocytes,CD1 lc+,and CD123+precursor dendritic cells produced by leukocytapheresis[J].Transfusion,2007,47(7):1241-1249.
[43]Xu H,Kramer M,Spengler HP,et al.Dendritic cells differentiated from human monocytes through a combination of IL-4,GM-CSF and IFN-gamma exhibit phenotype and function of blood dendritic cells[J].Adv Exp Med Biol,1995,378:75-8
[44]张玉梅,孙桂芝,周同,等.体外培养人树突状细胞分化成熟特性分析[J].中国微循环,2006,10(1):9-11.
[45]Guinet E,Yoshida K,Nouri-Shirazi M.Nicotinic environment affects the differentiation and functional maturation of monocytes derived dendritic cells [J].Immunol Lett.2004 Aug 15;95(1):45-55.
[46]Wang H,Huang H,Cai KY.The effect of oxidized low-density lipoprotein on the maturation and its immune function of monocyte-derived dendritic cells[J].Zhonghua Xin Xue Guan Bing Za Zhi.2008 Dec;36(12):1106-1109.
[47]冯刚,李胜富,李幼平,等.反义肽核酸对树突状细胞CD86表达的抑制作用[J].华西医大学报,2002,33(2):192-195.
[48]Peng Shao,Lu-Hang Zhao,Zhi-Chen,et al.Regulation on maturation and function of dendritic cells by Astragalus mongholicus polysaccharides[J].Int Immunopharmacol,2006,6:1161-1166.
[49]姚莉,梁晓俐,王德文.树突细胞的凋亡与调控[J].免疫学杂志,2003,19(3):96-99.
[50]Banchereau J,Steinman R M.Dendritic cells and the control of immunity[J].Nature,1998,392:245-252.
[1]Sheikine YA,Hansson GK.Chemokines as potential therapeutic targets in atherosclerosis.Curr Drug Targets,2006,7:13-27.
[2]Hallenbeck JM,Hansson GK,Becker KJ.Immunology of ischemic vascular disease:plaque to attack.Trends Immunol,2005,26:550-6.
[3]Falk E.Pathogenesis of atherosclerosis.J Am Coll Cardiol,2006,47:C7-12.
[4]Achar SA,Kundu S,Norcross WA.Diagnosis of acute coronary syndrome.Am Fam Physician,2005,72:119-26.
[5]Large GA.Contemporary management of acute coronary syndrome.Postgrad Med J,2005,81:217-22.
[6]Shen CX,Chen HZ,Ge JB.The role of inflammatory stress in acute coronary syndrome.Chin Med J (Engl),2004,117:133-9.
[7]Prasad A, Mathew V, Holmes DR Jr, et al.Current management of non-ST-segment-elevation acute coronary syndrome:reconciling the results of randomized controlled trials.Eur Heart J,2003,24:1544-53.
[8]Corrado E,Rizzo M,Tantillo R,et al.Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions:a 5-year follow-up study.Stroke,2006,37:482-6.
[9]Ford PJ,Gemmell E,Timms P,et al.Anti-P.gingivalis response correlates with atherosclerosis.J Dent Res,2007,86:35-40.
[10]Ausiello CM,Palazzo R,Spensieri F,et al.60-kDa heat shock protein of Chlamydia pneumoniae is a target of T-cell immune response.J Biol Regul Homeost Agents,2005,19:136-40.
[11]Mandal K,Foteinos G,Jahangiri M,et al.Role of antiheat shock protein 60 autoantibodies in atherosclerosis.Lupus,2005,14:742-6.
[12]Fields ML,Nish SA,Hondowicz BD,et al.The influence of effector T cells and Fas ligand on lupus-associated B cells.J Immunol,2005,175:104-11.
[13]Shibata Y,Ohata H,Yamashita M,et al.Immunologic response enhances atherosclerosis-type 1 helper T cell (Thl)-to-type 2 helper T cell (Th2) shift and calcified atherosclerosis in Bacillus Calmette-Guerin(BCG)-treated apolipoprotein E-knockout (apo E-/-) mice.Transl Res,2007,149:62-9.
[14]Hansson GK,Berne GP.Atherosclerosis and the immune system.Acta Paediatr Suppl,2004,93:63-9.
[15]Wick G,Schett G,Amberger A,et al.Is atherosclerosis an immunologically mediated disease?.Immunol Today,1995,16:27-33.
[16]Kaiser J.Genomics.Celera to end subscriptions and give data to public GenBank.Science,2005,308:775.
[17]Temple G,Lamesch P,Milstein S,et al.From genome to proteome:developing expression clone resources for the human genome.Hum Mol Genet,2006,15 Spec No 1:R31-43.
[18]Boyce JD,Adler B.How does Pasteurella multocida respond to the host environment?.Curr Opin Microbiol,2006,9:117-22.
[19]Deutsch S,Reymond A.The future is genome-wide.Genome Biol,2006,7:324.
[20]Kane MD.Technical issues in DNA microarray production and utilization:impact on clinical research.Expert Rev Mol Diagn,2005,5:649-54.
[21]Bracken MB.Genomic epidemiology of complex disease:the need for an electronic evidence-based approach to research synthesis.Am J Epidemiol,2005,162:297-301.
[22]Boguski MS.ENCODE and ChIP-chip in the genome era.Genomics,2004,83:347-8.
[23]Slater EP,Diehl SM,Langer P,et al.Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors.Eur J Endocrinol, 2006,154:587-98.
[24]Feng HC,Tsao SW,Ngan HY,et al.Differential gene expression identified in complete hydatidiform mole by combining suppression subtractive hybridization and cDNA microarray.Placenta,2006,27:521-6.
[25]Piepho HP.Optimal allocation in designs for assessing heterosis from cDNA gene expression data.Genetics,2005,171:359-64.
[26]Ylstra B,van den Ijssel P,Carvalho B,et al.BAC to the future! or oligonucleotides:a perspective for micro array comparative genomic hybridization(array CGH).Nucleic Acids Res,2006,34:445-50.
[27]Loy A,Bodrossy L.Highly parallel microbial diagnostics using oligonucleotide microarrays.Clin Chim Acta,2006,363:106-19.
[28]Brandt O,Hoheisel JD.Peptide nucleic acids on microarrays and other biosensors.Trends Biotechnol,2004,22:617-22.
[29]Zabel BA,Silverio AM,Butcher EC.Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood.J Immunol,2005,174:244-51.
[30]Moutaftsi M,Brennan P,Spector SA,et al.Impaired lymphoid chemokine-mediated migration due to a block on the chemokine receptor switch in human cytomegalovirus-infected dendritic cells.J Virol,2004,78:3046-54.
[31]Chieppa M,Bianchi G,Doni A,et al.Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program.J Immunol,2003,171:4552-60.
[32]Riol-Blanco L,Sanchez-Sanchez N,Torres A,et al.The chemokine receptor CCR7 activates in dendritic cells two signaling modules that independently regulate chemotaxis and migratory speed.J Immunol,2005,174:4070-80.
[33]张新华,钟翠平.树突状细胞与趋化因子的研究进展.解剖学杂志,2004.27 (1):93-96.
[34]孟哲峰.树突状细胞来源的趋化因子的免疫调节作用研究进展.国外医学.临床生物化学与检验学分册,2004.25(1):65-66,69.
[35]Yilmaz A,Weber J,Cicha I,et al.Decrease in circulating myeloid dendritic cell precursors in coronary artery disease.J Am Coll Cardiol,2006,48:70-80.
[36]Bauriedel G,Skowasch D,Welsch U,et al.Role of dendritic cells in specific atherosclerosis types.Eur Heart J,2006,27:116;author reply 116-7.
[37]De Palma R,Del Galdo F,Abbate G,et al.Patients with acute coronary syndrome show oligoclonal T-cell recruitment within unstable plaque:evidence for a local,intracoronary immunologic mechanism.Circulation,2006,113:640-6.
[38]李大主,Ranjit S,曾秋棠,等.老年急性冠状动脉综合征患者树突状细胞的功能状态.中华老年心脑血管病杂志.2004,6(5):308-310.
[39]李大主,Sharma Ranjit,曾秋棠,等.不稳定型心绞痛患者树突状细胞功能的研究.中国病理生理杂志.2005,21(4):732-732,737.
[40]Ranjit S,Dazhu L,Qiutang Z,et al.Differentiation of dendritic cells in monocyte cultures isolated from patients with unstable angina.Int J Cardiol,2004,97:551-5.
[41]Wu L,Dakic A.Development of dendritic cell system.Cell Mol Immunol,2004,1:112-8.
[42]Quah BJ,O'Neill HC.Maturation of function in dendritic cells for tolerance and immunity.J Cell Mol Med,2005,9:643-54.
[43]Doni A,Michela M,Bottazzi B,et al.Regulation of PTX3,a key component of humoral innate immunity in human dendritic cells:stimulation by IL-10 and inhibition by IFN-gamma.J Leukoc Biol,2006,79:797-802.
[44]Hasan U,Chaffois C,Gaillard C,et al.Human TLR10 is a functional receptor,expressed by B cells and plasmacytoid dendritic cells,which activates gene transcription through MyD88.J Immunol,2005,174:2942-50.
[45]Jin Y,Fuller L,Ciancio G,et al.Antigen presentation and immune regulatory capacity of immature and mature-enriched antigen presenting(dendritic)cells derived from human bone marrow.Hum Immunol,2004,65:93-103.
[46]Regnault A,Lankar D,Lacabanne V,et al.Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization.J Exp Med,1999,189:371-80.
[47]Tanaka Y,Mamalaki C,Stockinger B,et al.In vitro negative selection of alpha beta T cell receptor transgenic thymocytes by conditionally immortalized thymic cortical epithelial cell lines and dendritic cells.Eur J Immunol,1993,23:2614-21.
[48]Coates PT,Colvin BL,Ranganathan A,et al.CCR and CC chemokine expression in relation to Flt3 ligand-induced renal dendritic cell mobilization.Kidney Int,2004,66:1907-17.
[49]Yamagami S,Hamrah P,Miyamoto K,et al.CCR5 chemokine receptor mediates recruitment of MHC class Ⅱ-positive Langerhans cells in the mouse corneal epithelium.Invest Ophthalmol Vis Sci,2005,46:1201-7.
[50]Dewin DR,Catusse J,Gompels UA.Identification and characterization of U83A viral chemokine,a broad and potent beta-chemokine agonist for human CCRs with unique selectivity and inhibition by spliced isoform.J Immunol,2006,176:544-56.
[51]Zhang Y,Yoneyama H,Wang Y,et al.Mobilization of dendritic cell precursors into the circulation by administration of MIP-1alpha in mice.J Natl Cancer Inst,2004,96:201-9.
[52]陈兴国,池淑红,顾越英等.系统性红斑狼疮相关基因IFIT1的功能初探.中华风湿病学杂志,2004,8(7):395-399.
[53]徐祖森 周映.IFI16及其信号转导途径在系统性红斑狼疮发病中的作用.中华皮肤科杂志.2006,39(9):524-526.
[54]Kubach J,Becker C,Schmitt E,et al.Dendritic cells:sentinels of immunity and tolerance.Int J Hematol,2005,81:197-203.
[55]Hochweller K,Sweenie CH,Anderton SM.Immunological tolerance using synthetic peptides--basic mechanisms and clinical application.Curr Mol Med,2006,6:631-43.
[56]Li YP,Larger-Canard V,Marchal L,et al.The regulatory role of dendritic cells in the immune tolerance.Biomed Mater Eng,2006,16:S 163-70.
[1]Parashar D,Chauhan DS,Sharma VD,et al.Applications of real-time PCR technology to mycobacterial research.Indian J Med Res,2006,124:385-98.
[2]Honest H,Sharma S,Khan KS.Rapid tests for group B Streptococcus colonization in laboring women: a systematic review.Pediatrics,2006,117:1055-66.
[3]Espy MJ,Uhl JR,Sloan LM,et al.Real-time PCR in clinical microbiology:applications for routine laboratory testing.Clin Microbiol Rev,2006,19:165-256.
[4]Suzuki N,Yoshida A,Nakano Y.Quantitative analysis of multi-species oral biofilms by TaqMan Real-Time PCR.Clin Med Res,2005,3:176-85.
[5]Overbergh L,Giulietti A,Valckx D,et al.The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression.J Biomol Tech,2003,14:33-43.
[6]Giulietti A,Overbergh L,Valckx D,et al.An overview of real-time quantitative PCR: applications to quantify cytokine gene expression.Methods,2001,25:386-401.
[7]Valasek MA,Repa JJ.The power of real-time PCR.Adv Physiol Educ,2005,29:151-9.
[8]Jones SW,Dobson ME,Francesconi SC,et al.DNA assays for detection,identification,and individualization of select agent microorganisms.Croat Med J,2005,46:522-9.
[9]Bustin SA,Benes V,Nolan T,et al.Quantitative real-time RT-PCR--a perspective.J Mol Endocrinol,2005,34:597-601.
[10]Wang XS,Simmons Z,Liu W,et al.Differential expression of genes in amyotrophic lateral sclerosis revealed by profiling the post mortem cortex. Amyotroph Lateral Scler,2006,7:201-10.
[11]Boyer J,Allen WL,McLean EG,et al.Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer.Cancer Res,2006,66:2765-77.
[12]Wong LJ,Bai RK.Real-time quantitative polymerase chain reaction analysis of mitochondrial DNA point mutation.Methods Mol Biol,2006,335:187-200.
[13]Luthra R,Medeiros LJ.TaqMan reverse transcriptase-polymerase chain reaction coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type.Methods Mol Biol,2006,335:135-45.
[14]Elsayed S,Plewes K,Church D,et al.Use of molecular beacon probes for real-time PCR detection of Plasmodium falciparum and other Plasmodium species in peripheral blood specimens.J Clin Microbiol,2006,44:622-4.
[15]Gubala AJ,Proll DF.Molecular-beacon multiplex real-time PCR assay for detection of Vibrio cholerae.Appl Environ Microbiol,2006,72:6424-8.
[16]Sinsimer D,Leekha S,Park S,et al.Use of a multiplex molecular beacon platform for rapid detection of methicillin and vancomycin resistance in Staphylococcus aureus.J Clin Microbiol,2005,43:4585-91.
[17]Yang ZZ,Habib M,Shuai JB,et al.Detection of PCV2 DNA by SYBR Green I-based quantitative PCR.J Zhejiang Univ Sci B,2007,8:162-9.
[18]Kohdera U,Kino M,Ito M.Detection of adenovirus DNA in throat swabs and blood by SYBR green real-time PCR assay in patients with adenovirus-associated tonsillitis.Jpn J Infect Dis,2006,59:394-6.
[19]Ivyna Bong PN,Patricia L,Pauline B,et al.Quantitative analysis of the expression of p53 gene in colorectal carcinoma by using real-time PCR.Trop Biomed,2006,23:53-9.
[20]Feng JL,Chen SN,Tang XS,et al.Quantitative determination of cucumber mosaic virus genome RNAs in virions by real-time reverse transcription-polymerase chain reaction.Acta Biochim Biophys Sin (Shanghai),2006,38:669-76.
[21]Gomes AL,Melo FL,Werkhauser RP,et al.Development of a real time polymerase chain reaction for quantitation of Schistosoma mansoni DNA.Mem Inst Oswaldo Cruz,2006,101 Suppl 1:133-6.
[22]Mata JF,Scrideli CA,Queiroz RP,et al.Cytosine arabinoside-metabolizing enzyme genes are underexpressed in children with MLL gene-rearranged acute lymphoblastic leukemia.Braz J Med Biol Res,2006,39:1417-23.
[23]Morey JS,Ryan JC,Van Dolah FM.Microarray validation:factors influencing correlation between oligonucleotide microarrays and real-time PCR.Biol Proced Online,2006,8:175-93.
[24]Christensen DR,Hartman LJ,Loveless BM,et al.Detection of biological threat agents by real-time PCR:comparison of assay performance on the R.A.P.I.D,the LightCycler,and the Smart Cycler platforms.Clin Chem,2006,52:141-5.
[25]Yu Z,Michel FC Jr,Hansen G,et al.Development and application of real-time PCR assays for quantification of genes encoding tetracycline resistance.Appl Environ Microbiol,2005,71:6926-33.
[26]Yang YH,Nam MS,Yang ES.Rapid prenatal diagnosis of trisomy 21 by real-time quantitative polymerase chain reaction with amplification of small tandem repeats and S100B in chromosome 21.Yonsei Med J,2005,46:193-7.
[27]Cui W,Taub DD,Gardner K.qPrimerDepot:a primer database for quantitative real time PCR.Nucleic Acids Res,2007,35:D805-9.
[28]Moriya Y,Nakamura T,Okamura N,et al.Comparison of synthetic DNA templates with authentic cDNA templates in terms of quantification by real-time quantitative reverse transcription polymerase chain reaction.Biol Pharm Bull, 2006,29:535-8.
[29]Brettar I,Labrenz M,Flavier S,et al.Identification of a Thiomicrospira denitrificans-like epsilonproteobacterium as a catalyst for autotrophic denitrification in the central Baltic Sea.Appl Environ Microbiol,2006,72:1364-72.
[30]Dussault AA,Pouliot M.Rapid and simple comparison of messenger RNA levels using real-time PCR.Biol Proced Online,2006,8:1-10.
[31]Zheng Y,Josefowicz SZ,Kas A,et al.Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells.Nature,2007,445:936-40.
[32]Kobasa D,Jones SM,Shinya K,et al.Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus.Nature,2007,445:319-23.
[33]Redon R,Ishikawa S,Fitch KR,et al.Global variation in copy number in the human genome.Nature,2006,444:444-54.
[34]Baur JA,Pearson KJ,Price NL,et al.Resveratrol improves health and survival of mice on a high-calorie diet.Nature,2006,444:337-42.
[35]Mouchel CF,Osmont KS,Hardtke CS.BRX mediates feedback between brassinosteroid levels and auxin signalling in root growth.Nature,2006,443:458-61.
[36]Abzhanov A,Kuo WP,Hartmann C,et al.The calmodulin pathway and evolution of elongated beak morphology in Darwin's finches.Nature,2006,442:563-7.
[37]Gilchrist M,Thorsson V,Li B,et al.Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4.Nature,2006,441:173-8.
1.马文丽,郑文岭.DNA芯片技术的方法与应用[M].广州:广东科技出版社,2002:7-5359-3065-4.
2.Schena,M.Genome analysis with gene expression microarrays.BioEssays 18,427-431(1996).
3.Lockhart,D.J.et al.Expression monitoring by hybridization tohigh-densityoligonucleotide arrays.Nature Biotechnol.13,1675-1680(1996).
4.Southern,E.M.Blotting at 25.Trends Biochem.Sci.25,585-588(2000).
5.Wodicka,L.,Dong,H.,Mittmann,M.,Ho,M.H.& Lockhart,D.J.Genome-wideexpression monitoring in Saccharomyce cerevisiae.Nature Biotechnol.15,1359-1367(1997).
6.李凌,马文丽.DNA芯片技术研究进展[J].中国生物化学与分子生物学报,2000,16(2):151-155
7.Yuen,T.,Wurmbach,E.,Pfeffer,R.L.,Ebersole,B.J.& Sealfon,S.C.Accuracy andcalibration of commercial oligonucleotide and custom cDNA microarrays.NucleicAcids Res.30,e48(2002).
8.Schena,M.et al.Microarrays:biotechnology's discovery platform forfunctionalgenomics.Trends Biotechnol.16,301-306(1998).
9.Rose,D.Microfluidic technologies and instrumentation for printing DNA microarrays.in Microarray Biochip Technology 5th edn.(ed.Schena,M.)19-38Eaton Publishing,Natick,MA,2000).
10.Carr,D.B.,Somogyi,R.& Miehaels,G.Templates for looking at gene expressionelustering.Statistical Computing and Graphics Newsletter 8,20-29(1997).
11.Eisen,M.B.,Spellman,P.T.,Brown,P.O.& Botstein,D.Cluster analysis and displayof genome-wide expression patterns.Proc.Natl.Acad.Sci.USA 95,14863-14868 (1998).
12.Bjorkholm,B.et al.Comparison of genetic divergence and fitness between twosubclones of Helicobacter pylori.Infect.Immun.69,7832-7838 (2001).
13.Wang,D.,Liu,S.,Trummer,B.J.,Deng,C.& Wang,A.Carbohydrate microarraysfor the recognition of cross-reactive molecular markers of microbes and hostcells.Nature Biotechnol.20,275-281(2002).
14.DeRisi,J.L.,Iyer,V.R.& Brown,P.O.Exploring the metabolic and genetic controlof gene expression on a genomic scale.Science 278,680-686 (1997).
15.Heller,R.A.et al.Discovery and analysis of inflammatory disease-related genesusing cDNA microarrays.Proc.Natl.Acad.Sci.USA 94,2150-2155 (1997).
16.Robinl,.Stears,Todd Martinsky&Mark Schena,Trends in microarray analysis .Nature medicine,January 2003.
17.Xiong,M,Li,W.,Zhao,J.,Jin,L.& Boerwinkle,E.Feature (gene) selection ingene expression-based tumor classification.Mol.Genet.Metab.73,239-247(2001).
18.Selaru,F.M.et al.Artificial neural networks distinguish among subtypes of neoplasticcolorectal lesions.Gastroenterology 122,606-613 (2002).
19.MacBeath,G.& Schreiber,S.L.Printing proteins as microarrays for high-throughputfunction determination.Science 289,1760-1763 (2000).
20.Wilson,D.S.& Nock,S.Functional protein microarrays.Curr.Opin.Chem.Biol.6,81-85 (2002).21
21.Cao,Y.C.,Jin,R.& Mirkin,C.A.Nanoparticles with Raman spectroscopic fingerprintsfor DNA and RNA detection.Science 297,1536-1540 (2002).
22.Fodor,S.P.et al.Light-directed,spatially addressable parallel chemical synthesis.Science 251,767-773 (1991).
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |